primaquine has been researched along with Malaria, Falciparum in 207 studies
Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404)
primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.
Malaria, Falciparum: Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Single low-dose primaquine (SLDPQ) effectively blocks the transmission of Plasmodium falciparum malaria, but anxiety remains regarding its haemolytic potential in patients with glucose-6-phopshate dehydrogenase (G6PD) deficiency." | 9.69 | Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo. ( Bamisaiye, A; Basara, BB; Baseke, J; Day, NPJ; Fanello, C; Kayembe, DK; Maitland, K; Muhindo, R; Mukaka, M; Namayanja, C; Ndjowo, PO; Okalebo, CB; Olupot-Olupot, P; Onyamboko, MA; Onyas, P; Taya, C; Taylor, WRJ; Titin, H; Uyoga, S; Were, W; Williams, TN, 2023) |
| "5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment." | 9.69 | Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment. ( Batty, KT; Davis, TME; Kasian, B; Laman, M; Lorry, L; Manning, L; Moore, BR; Pomat, W; Robinson, LJ; Salman, S; Tesine, P; Woon, SA; Yadi, G; Yambo, P, 2023) |
| "Adults with Plasmodium falciparum malaria were randomized to receive 1 of 3 artemisinin combination therapies (ACTs) with or without primaquine (0." | 9.24 | Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial. ( Fall, FB; Faye, B; Faye, BT; Gaye, O; Greenwood, B; Milligan, P; Ndiaye, JL; Ndiaye, M; Poirot, E; Sow, D; Sylla, K; Tine, RC; Wang, D, 2017) |
| "Single low doses of primaquine, when added to artemisinin-based combination therapy, might prevent transmission of Plasmodium falciparum malaria to mosquitoes." | 9.22 | Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. ( Baber, I; Bousema, T; Brown, JM; Chen, I; Diawara, H; Dicko, A; Gosling, R; Hwang, J; Keita, S; Koita, F; Lanke, K; Mahamar, A; McCulloch, C; Niemi, M; Nosten, F; Pett, H; Poirot, E; Sanogo, K; Soumare, HM; Traore, SF, 2016) |
| "This study assessed the safety of the new World Health Organization (WHO) recommendation of adding a single low-dose of primaquine (PQ) to standard artemisinin-based combination therapy (ACT), regardless of individual glucose-6-phosphate dehydrogenase (G6PD) status, for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania." | 9.22 | Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. ( Björkman, A; Gosling, R; Jovel, I; Mårtensson, A; Mmbando, BP; Mwaiswelo, R; Ngasala, BE; Poirot, E; Premji, Z, 2016) |
| "The efficacy of a single dose of 45 mg primaquine, as a gametocytocidal agent, was assessed in Mumbai, India, among adults with uncomplicated or severe Plasmodium falciparum malaria." | 9.11 | A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. ( Aigal, U; Chogle, AR; Dalvi, SS; Gogtay, NJ; Kamtekar, KD; Karnad, DR; Kshirsagar, NA, 2004) |
| "To improve upon the efficacy of primaquine prophylaxis for malaria (94%, Plasmodium falciparum malaria; 85%, Plasmodium vivax malaria), we administered chloroquine (300 mg weekly) in combination with primaquine (30 mg daily) to nonimmune Colombian soldiers during 16 weeks of patrol in a region of endemicity and for a further 1 week in base camp." | 9.09 | Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. ( Berman, J; Herrera, R; Padilla, J; Rodriquez, M; Sanchez, J; Soto, J; Toledo, J, 1999) |
| "Of late there have been accounts of therapeutic failure and chloroquine resistance in Plasmodium vivax malaria especially from Southeast Asian regions." | 7.81 | Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. ( Acharya, RV; Acharya, V; Belle, J; Hande, MH; Kamath, A; Rishikesh, K; Saravu, K; Shastry, AB; Vidyasagar, S, 2015) |
| " Blood samples were collected for parasite detection (by microscopy and PCR), molecular genotyping and pharmacokinetic analyses." | 6.94 | Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tan ( Barnes, R; Björkman, A; Kitabi, EN; Mårtensson, A; Mhamilawa, LE; Mmbando, BP; Morris, U; Ngasala, B; Soe, AP, 2020) |
| "Single low-dose primaquine (SLDPQ) effectively blocks the transmission of Plasmodium falciparum malaria, but anxiety remains regarding its haemolytic potential in patients with glucose-6-phopshate dehydrogenase (G6PD) deficiency." | 5.69 | Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo. ( Bamisaiye, A; Basara, BB; Baseke, J; Day, NPJ; Fanello, C; Kayembe, DK; Maitland, K; Muhindo, R; Mukaka, M; Namayanja, C; Ndjowo, PO; Okalebo, CB; Olupot-Olupot, P; Onyamboko, MA; Onyas, P; Taya, C; Taylor, WRJ; Titin, H; Uyoga, S; Were, W; Williams, TN, 2023) |
| "5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment." | 5.69 | Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment. ( Batty, KT; Davis, TME; Kasian, B; Laman, M; Lorry, L; Manning, L; Moore, BR; Pomat, W; Robinson, LJ; Salman, S; Tesine, P; Woon, SA; Yadi, G; Yambo, P, 2023) |
| " Patients with uncomplicated falciparum malaria, G6PD activity of ≥70% of the adjusted male median (AMM) and haemoglobin levels ≥8g/dl are recruited into the study and randomized to either receive standard schizonticidal treatment plus 7-day high dose primaquine (total dose 7mg/kg) or standard care in a 1:1 ratio." | 5.51 | Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA). ( Abate, DT; Alam, MS; Anose, RT; Baird, K; Christian, M; Degaga, TS; Hailu, A; Hossain, MS; Karahalios, A; Kibria, MG; Kidane, FG; Lee, G; Ley, B; Mnjala, H; Price, RN; Rajasekhar, M; Rumaseb, A; Simpson, JA; Sutanto, I; Tego, TT; Thriemer, K; Weston, S; Woyessa, A, 2022) |
| " We modelled an anthropometric database of 661,979 African individuals aged ≥6 months (549,127 healthy individuals, 28,466 malaria patients and 84,386 individuals with other infections/illnesses) by the Box-Cox transformation power exponential and tested PQ doses of 1-15 mg base, selecting dosing groups based on calculated mg/kg PQ doses." | 5.48 | Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. ( Achan, J; Affara, M; Amambua, AN; Aseffa, A; Barnes, KI; Bejon, P; Berkley, JA; Brasseur, P; D'Alessandro, U; Day, NP; Diakite, M; Dorsey, G; Fairhurst, RM; Fanello, C; Gadisa, E; Henry, MC; John, C; Jones, J; Kapulu, M; Kremsner, P; Lasry, E; Loolpapit, M; Lutumba, P; Maitland, K; Malenga, G; Matangila, J; Mavoko, M; Molyneux, M; Mukaka, M; Naw, HK; Nwakanma, D; Obonyo, C; Okebe, J; Onyamboko, M; Piola, P; Randremanana, R; Rwagacondo, C; Schramm, B; Sirima, SB; Taylor, WR; van Geertruyden, JP; White, NJ; Williams, TN; Yah, Z, 2018) |
| "Primaquine is an important gametocytocidal drug that is combined with conventional malaria treatment for prevention of Plasmodium falciparum malaria transmission." | 5.34 | Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether-lumefantrine. ( Abdulla, S; Bousema, T; Drakeley, C; Hamad, A; Mbaga, TA; Mihayo, M; Mosha, D; Shekalaghe, S, 2020) |
| "Adults with Plasmodium falciparum malaria were randomized to receive 1 of 3 artemisinin combination therapies (ACTs) with or without primaquine (0." | 5.24 | Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial. ( Fall, FB; Faye, B; Faye, BT; Gaye, O; Greenwood, B; Milligan, P; Ndiaye, JL; Ndiaye, M; Poirot, E; Sow, D; Sylla, K; Tine, RC; Wang, D, 2017) |
| "Single low doses of primaquine, when added to artemisinin-based combination therapy, might prevent transmission of Plasmodium falciparum malaria to mosquitoes." | 5.22 | Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial. ( Baber, I; Bousema, T; Brown, JM; Chen, I; Diawara, H; Dicko, A; Gosling, R; Hwang, J; Keita, S; Koita, F; Lanke, K; Mahamar, A; McCulloch, C; Niemi, M; Nosten, F; Pett, H; Poirot, E; Sanogo, K; Soumare, HM; Traore, SF, 2016) |
| "This study assessed the safety of the new World Health Organization (WHO) recommendation of adding a single low-dose of primaquine (PQ) to standard artemisinin-based combination therapy (ACT), regardless of individual glucose-6-phosphate dehydrogenase (G6PD) status, for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania." | 5.22 | Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania. ( Björkman, A; Gosling, R; Jovel, I; Mårtensson, A; Mmbando, BP; Mwaiswelo, R; Ngasala, BE; Poirot, E; Premji, Z, 2016) |
| "To determine the efficacy, safety and tolerability of an alternative short-course, artemisinin-based combination therapy for acute uncomplicated Plasmodium falciparum malaria, we compared Artequick--a fixed-dosed combination of artemisinin (80 mg), piperaquine (400 mg), and primaquine (4 mg), per tablet--with a standard regimen of artesunate-mefloquine." | 5.13 | Efficacy of Artequick versus artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand. ( Brittenham, GM; Kano, S; Krudsood, S; Li, G; Looareesuwan, S; Pengruksa, C; Phophak, N; Tangpukdee, N; Thanachartwet, V; Wilairatana, P, 2008) |
| " falciparum gametocytes may persist after treatment with sulphadoxine-pyrimethamine (SP) plus artesunate (AS) and contribute considerably to malaria transmission." | 5.12 | Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. ( Alifrangis, M; Bousema, T; Drakeley, C; Enevold, A; Gosling, R; Mosha, F; Ndaro, A; Sauerwein, R; Shekalaghe, S; van Meegeren, M, 2007) |
| "The activities of primaquine in combination with quinine or artesunate against asexual- and sexual-stage parasites were assessed in 176 adult Thai patients with uncomplicated Plasmodium falciparum malaria." | 5.11 | Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria. ( Chantra, A; Chotivanich, K; Clemens, R; Looareesuwan, S; Pukrittayakamee, S; White, NJ, 2004) |
| "The efficacy of a single dose of 45 mg primaquine, as a gametocytocidal agent, was assessed in Mumbai, India, among adults with uncomplicated or severe Plasmodium falciparum malaria." | 5.11 | A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India. ( Aigal, U; Chogle, AR; Dalvi, SS; Gogtay, NJ; Kamtekar, KD; Karnad, DR; Kshirsagar, NA, 2004) |
| "An open randomized controlled study of mefloquine-artesunate and mefloquine-primaquine for the treatment of uncomplicated Plasmodium falciparum malaria was carried out in Kanchanaburi in the Saiyok District in western Thailand." | 5.10 | The efficacy of combined mefloquine-artesunate versus mefloquine-primaquine on subsequent development of Plasmodium falciparum gametocytemia. ( Chaikachonpatd, S; Chanthapakajee, K; Chindarat, S; Kaewkaukul, N; Lim, K; Silpasakorn, S; Suputtamongkol, Y; Thamlikitkul, V, 2003) |
| "To improve upon the efficacy of primaquine prophylaxis for malaria (94%, Plasmodium falciparum malaria; 85%, Plasmodium vivax malaria), we administered chloroquine (300 mg weekly) in combination with primaquine (30 mg daily) to nonimmune Colombian soldiers during 16 weeks of patrol in a region of endemicity and for a further 1 week in base camp." | 5.09 | Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers. ( Berman, J; Herrera, R; Padilla, J; Rodriquez, M; Sanchez, J; Soto, J; Toledo, J, 1999) |
| "Following the recent successes of malaria control in sub-Saharan Africa, the gametocytocidal drug primaquine needs evaluation as a tool to further reduce the transmission of Plasmodium falciparum malaria." | 4.88 | Rationale for short course primaquine in Africa to interrupt malaria transmission. ( Bousema, T; Drakeley, C; Eziefula, AC; Gosling, R; Hsiang, MS; Hwang, J; von Seidlein, L, 2012) |
| "Primaquine is a gametocytocidal drug recommended by the World Health Organization (WHO) in a single-low dose combined with artemisinin-based combination therapy (ACT) for the treatment and prevention of Plasmodium falciparum malaria transmission." | 4.02 | Safety monitoring experience of single-low dose primaquine co-administered with artemether-lumefantrine among providers and patients in routine healthcare practice: a qualitative study in Eastern Tanzania. ( Abdulla, S; Drakeley, C; Gosling, R; Kakolwa, MA; Mahende, MK; Masanja, H; Mosha, D; Wamoyi, J, 2021) |
| "Primaquine (PQ) is a commonly used drug that can prevent the transmission of Plasmodium falciparum malaria, however toxicity limits its use." | 3.88 | Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity. ( Ester, K; Kaiser, M; Kralj, M; Levatić, J; Pavić, K; Perković, I; Rottmann, M; Supek, F; Uzelac, L; Zorc, B, 2018) |
| "Of late there have been accounts of therapeutic failure and chloroquine resistance in Plasmodium vivax malaria especially from Southeast Asian regions." | 3.81 | Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. ( Acharya, RV; Acharya, V; Belle, J; Hande, MH; Kamath, A; Rishikesh, K; Saravu, K; Shastry, AB; Vidyasagar, S, 2015) |
| "Recent studies have shown that Plasmodium falciparum malaria parasites in Pailin province, along the border between Thailand and Cambodia, have become resistant to artemisinin derivatives." | 3.78 | Focused Screening and Treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant P. falciparum, Pailin, Cambodia. ( Ariey, F; Bjorge, S; Chea, N; Christophel, EM; Duong, S; Habib, N; Hoyer, S; Kheng, S; Khim, N; Kim, S; Mellor, S; Menard, D; Newman, RD; Nguon, S; Ros, S; Sophal, U; Sum, S; Thompson, MM; Thomson, A; Top, S; Witkowski, B; Yeang, C; Yeung, S; Yok, S, 2012) |
| "In Honduras, chloroquine and primaquine are recommended and still appear to be effective for treatment of Plasmodium falciparum and Plasmodium vivax malaria." | 3.77 | Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America. ( Alger, J; Banegas, E; Bjorkman, A; Enamorado, IG; Ferreira, PE; Fontecha, G; Jovel, IT; Mejía, RE; Piedade, R; Ursing, J; Veiga, MI, 2011) |
| "A combination of chloroquine (CQ) and primaquine (PQ) had been used as the first-line treatment of uncomplicated Plasmodium falciparum malaria in Rangamati, Bangladesh until the end of 2004." | 3.77 | Efficacy of chloroquine plus primaquine treatment and pfcrt mutation in uncomplicated falciparum malaria patients in Rangamati, Bangladesh. ( Arita, N; Chowdhury, MS; Kawabata, M; Kawai, A; Matsumoto, Y; Saito-Ito, A, 2011) |
| " Sexual and asexual parasite dynamics were thus evaluated in patients involved in antimalarial drug efficacy studies by using combined treatment with and without artemisinin derivatives for treating uncomplicated acute Plasmodium falciparum malaria in Antioquia, Colombia." | 3.76 | Dynamics of Plasmodium falciparum parasitemia regarding combined treatment regimens for acute uncomplicated malaria, Antioquia, Colombia. ( Alvarez, G; Blair, S; Piñeros, JG; Ríos, A; Tobón, A, 2010) |
| " knowlesi infection had uncomplicated malaria that responded to chloroquine and primaquine treatment." | 3.75 | Clinical and laboratory features of human Plasmodium knowlesi infection. ( Cox-Singh, J; Daneshvar, C; Davis, TM; Divis, PC; Rafa'ee, MZ; Singh, B; Zakaria, SK, 2009) |
| " We now demonstrate the ability of 2-tert-butylprimaquine to inhibit in vitro beta-hematin formation, to form a complex with heme with a stoichiometry of 1:1, and to enhance heme-induced hemolysis." | 3.74 | 2-tert-butyl-8-quinolinamines exhibit potent blood schizontocidal antimalarial activity via inhibition of heme crystallization. ( Harada, S; Huy, NT; Jain, M; Jain, R; Kamei, K; Kaur, K; Mizunuma, K; Nhien, NT; Uyen, DT, 2007) |
| "The influence of combinations containing the blood schizontocides chloroquine (CQ) or mefloquine (MEF), together with the 8-aminoquinolines (8AQ) primaquine (PQ) or the new, long-acting compound, tafenoquine (TAF), on the rate of selection of resistance to the individual compounds was examined using the asexual, intra-erythrocytic stages in rodent malaria models." | 3.72 | The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines. ( Peters, W; Robinson, BL; Stewart, LB, 2003) |
| " Participants were randomly assigned (1:1) to receive single low-dose primaquine combined with either artemether-lumefantrine or dihydroartemisinin-piperaquine, dosed by bodyweight." | 3.30 | Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, n ( Abongo, G; Basara, BB; Baseke, J; Bongo, GS; Day, NJP; Dhorda, M; Dondorp, AM; Fanello, C; Kayembe, DK; Maitland, K; Muhindo, R; Mukaka, M; Namayanja, C; Ndjowo, PO; Okalebo, CB; Olupot-Olupot, P; Onyamboko, MA; Onyas, P; Peerawaranun, P; Tarning, J; Taya, C; Taylor, WR; Titin, H; Uyoga, S; Waithira, N; Weere, W; Williams, TN, 2023) |
| "Primaquine radical cure has the potential to reduce P vivax recurrences in patients presenting with P falciparum as well as P vivax malaria but is undermined by poor adherence to the currently recommended 14-day regimen." | 3.11 | Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. ( Burdam, FH; Candrawati, F; Indrawanti, R; Kenangalem, E; Ley, B; Meagher, N; Poespoprodjo, JR; Price, DJ; Price, RN; Simpson, JA; Thriemer, K; Trianty, L, 2022) |
| " Nanotechnology-based drug delivery methods are highly specific, require a lower dose, offer more bioavailability with prolonged drug release and stay in the body longer." | 3.01 | Role of Nanomedicines in Controlling Malaria: A Review. ( Bohidar, HB; Rawat, K; Sharma, S, 2023) |
| " Blood samples were collected for parasite detection (by microscopy and PCR), molecular genotyping and pharmacokinetic analyses." | 2.94 | Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tan ( Barnes, R; Björkman, A; Kitabi, EN; Mårtensson, A; Mhamilawa, LE; Mmbando, BP; Morris, U; Ngasala, B; Soe, AP, 2020) |
| " Occurrence of adverse events was similar in both groups, except for vomiting, which was more frequent in the MB than in the PQ arm (20/50 vs 7/50, p = 0." | 2.90 | Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial. ( Compaoré, G; Coulibaly, B; D Alessandro, U; Jahn, A; Kieser, M; Klose, C; Krisam, J; Lu, G; Meissner, P; Mendes Jorge, M; Mockenhaupt, FP; Müller, O; Nebie, E; Ouermi, L; Sié, A, 2019) |
| " Day 7 lumefantrine concentrations and the number and nature of adverse events were similar between study arms; only one serious adverse event occurred (renal impairment in the no primaquine arm)." | 2.90 | Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial. ( Allen, E; Barnes, KI; Frean, J; Mabuza, A; Malatje, G; Raman, J; Swanepoel, H; Wiesner, L; Workman, L, 2019) |
| " After exclusion of blue urine, adverse events were similar across all groups (59 [74%] of 80 participants had 162 adverse events overall, 145 [90%] of which were mild)." | 2.87 | Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial. ( Bousema, T; Bradley, J; Brown, JM; Chen, I; Diarra, K; Diawara, H; Dicko, A; Drakeley, C; Gosling, R; Hwang, J; Issiaka, D; Keita, S; Kone, DT; Lanke, K; Mahamar, A; McCulloch, C; Müller, O; Roh, ME; Sanogo, K; Soumare, HM; Srinivasan, V; Stone, WJR; Traore, SF, 2018) |
| " None of the study participants developed moderate or severe anemia; there were no severe adverse events." | 2.87 | Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials. ( Affara, M; Bastiaens, GJH; Bougouma, EC; Bousema, T; Bradley, J; Coulibaly, SA; d'Alessandro, U; Drakeley, C; Gonçalves, BP; Lanke, KHW; Nébié, I; Niemi, M; Okebe, J; Ouédraogo, A; Pett, HE; Sanou, GS; Sirima, SB; Tiono, AB, 2018) |
| "vivax malaria were treated with AS/SP." | 2.87 | Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan. ( Abdelbagi, H; Basheir, HM; Boshara, SA; Chen, I; Elobied, ME; Elsafi, HMH; Gosling, R; Gumaa, SA; Hamid, MMA; Hamid, T; Ley, B; Mahgoub, NS; Marfurt, J; Price, RN; Thriemer, K, 2018) |
| "G6PD deficiency is an inherited X-linked enzymatic defect that affects an estimated 400 million people around the world with high frequencies (15-20%) in populations living in malarious areas." | 2.82 | Single Low Dose Primaquine (0.25 mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects. ( Bancone, G; Chowwiwat, N; Gornsawun, G; Kajeechiwa, L; Kiricharoen, NL; Ling, CL; Moo, PK; Moore, KA; Nosten, F; Nosten, S; Nyo, SN; Poodpanya, L; Rakthinthong, S; Somsakchaicharoen, R; Thinraow, S; Thwin, MM; White, NJ; Wiladphaingern, J, 2016) |
| " Absolute and fractional changes in haemoglobin concentration within a week and adverse effects within 28 days of treatment initiation were characterised and compared between primaquine and no primaquine arms using random intercept models." | 2.82 | Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data. ( Allen, EN; Bancone, G; Barnes, KI; Bastiaens, GJH; Bjorkman, A; Bousema, T; Brown, JM; Chen, I; Craig, E; D'Alessandro, U; Dicko, AA; Drakeley, CJ; El-Sayed, B; Elzaki, SE; Eziefula, AC; Gonçalves, BP; Gosling, R; Guerin, PJ; Hamid, MMA; Humphreys, GS; Kaneko, A; Kariuki, S; Kennon, K; Khan, W; Kwambai, TK; Ley, B; Martensson, A; Mwaiswelo, RO; Ngasala, BE; Nosten, F; Okebe, J; Poirot, E; Price, RN; Raman, J; Samuels, AM; Smit, MR; Stepniewska, K; Stergachis, A; Stone, WJR; Sutanto, I; Ter Kuile, F; Tine, RC; Tiono, AB; White, NJ; Yilma, D, 2022) |
| "Both primaquine arms had lower gametocyte prevalences after day 3 compared to the placebo arm, regardless of gametocyte detection method." | 2.82 | Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial. ( Bougouma, EC; Bousema, T; Bradley, J; Diarra, A; Drakeley, C; Eziefula, AC; Gonçalves, BP; Guelbéogo, WM; Lanke, K; Nebie, I; Ouédraogo, A; Pett, H; Siaka, D; Sirima, SB; Tiono, AB, 2016) |
| "Pyronaridine-artesunate is a newly introduced artemisinin-based combination treatment which may be deployed together with primaquine." | 2.80 | Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. ( Ashley, EA; Blessborn, D; Chairat, K; Day, NP; Hanboonkunupakarn, B; Jittamala, P; Lee, SJ; Nosten, F; Panapipat, S; Pukrittayakamee, S; Tarning, J; Thana, P; White, NJ, 2015) |
| " We assessed the dose-response association of single-dose primaquine for gametocyte clearance and for safety in P falciparum malaria." | 2.79 | Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial. ( Bousema, T; Bradley, J; Drakeley, C; Eziefula, AC; Gabagaya, G; Grignard, L; Kamya, M; Lanke, KH; Mpimbaza, A; Nsobya, S; Owaraganise, A; Staedke, SG; Wanzira, H; Webb, EL; White, NJ; Yeung, S, 2014) |
| "Primaquine was well tolerated and could be administered along with an artemisinin combination therapy as the first-line therapy." | 2.78 | Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes. ( Anvikar, A; Juliano, JJ; MacDonald, PD; Meshnick, SR; Mishra, N; Poole, C; Schapira, A; Shah, NK; Srivastava, B; Valecha, N, 2013) |
| "Primaquine treatment also reduced the risk of quantitative real-time polymerase chain reaction- and light microscopy-positive P." | 2.77 | Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. ( Alonso, PL; Bassat, Q; Betuela, I; de Lazzari, E; Del Portillo, HA; Kiniboro, B; Mueller, I; Rosanas-Urgell, A; Samol, L; Siba, P; Stanisic, DI, 2012) |
| "Chloroquine combined with primaquine was evaluated for therapy of uncomplicated malaria caused by Plasmodium falciparum in nonimmune Javanese migrants to northeastern Papua, Indonesia." | 2.70 | Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. ( Ayomi, E; Baird, JK; Basri, H; Fryauff, DJ; Hoffman, SL; Sutanihardja, A; Wiady, I, 2002) |
| "To evaluate the efficacy and side effects of artemether combined with primaquine in the treatment of falciparum malaria." | 2.70 | [A study of artemether combined with primaquine in the treatment of falciparum malaria]. ( Elie, N; Gao, YQ; Huang, JR, 2001) |
| "Primaquine was as well tolerated as placebo." | 2.70 | Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. ( Baird, JK; Bangs, MJ; Barcus, MJ; Basri, H; Fryauff, DJ; Gramzinski, R; Hoffman, SL; Jones, TR; Kusumaningsih, M; Lacy, MD; Ling, J; Maguire, JD; Sismadi, P; Wiady, I, 2001) |
| "Halofantrine-primaquine was significantly more effective than chloroquine-primaquine against falciparum malaria (P < 0." | 2.68 | Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia. ( Baird, JK; Bangs, MJ; Basri, H; Fryauff, DJ; Harjosuwarno, S; Hoffman, SL; Richie, TL; Subianto, B; Tjitra, E; Wiady, I, 1997) |
| "Primaquine was tested as a prophylactic drug against Plasmodium falciparum in a region in western Kenya in which malaria is holoendemic." | 2.68 | Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. ( Hoffman, SL; Johnson, A; Koech, D; Oloo, AJ; Weiss, WR, 1995) |
| "Primaquine was better tolerated than chloroquine." | 2.68 | Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. ( Baird, JK; Bangs, MJ; Basri, H; Fryauff, DJ; Leksana, B; Masbar, S; Richie, TL; Subianto, B; Wiady, I, 1995) |
| " All but one death followed multiple dosing to prevent vivax malaria relapse." | 2.50 | Primaquine: the risks and the benefits. ( Ashley, EA; Recht, J; White, NJ, 2014) |
| " For optimal efficacy, treatment regimens must be adjusted with regard to dosage of primaquine and association with halofantrine, mefloquine or other new antimalarial agents." | 2.41 | [Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax]. ( Granier, H; Klotz, F; Martin, J; Nicolas, X, 2000) |
| " Further research is needed to determine the best dosage regimen for antimalarial drugs used for chemoprophylaxis in children." | 2.41 | Antimalarial chemoprophylaxis in infants and children. ( Kramer, MH; Lobel, HO, 2001) |
| "Primaquine (PQ) is an essential antimalarial drug but despite being developed over 70 years ago, its mode of action is unclear." | 1.51 | Antimalarial activity of primaquine operates via a two-step biochemical relay. ( Alano, P; Baker, DA; Bhatia, SN; Biagini, GA; Camarda, G; Jirawatcharadech, P; Leung, S; March, S; Miller, AB; O'Neill, PM; Paine, MJI; Priestley, RS; Saif, A; Ward, SA; Wong, MHL, 2019) |
| " We modelled an anthropometric database of 661,979 African individuals aged ≥6 months (549,127 healthy individuals, 28,466 malaria patients and 84,386 individuals with other infections/illnesses) by the Box-Cox transformation power exponential and tested PQ doses of 1-15 mg base, selecting dosing groups based on calculated mg/kg PQ doses." | 1.48 | Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. ( Achan, J; Affara, M; Amambua, AN; Aseffa, A; Barnes, KI; Bejon, P; Berkley, JA; Brasseur, P; D'Alessandro, U; Day, NP; Diakite, M; Dorsey, G; Fairhurst, RM; Fanello, C; Gadisa, E; Henry, MC; John, C; Jones, J; Kapulu, M; Kremsner, P; Lasry, E; Loolpapit, M; Lutumba, P; Maitland, K; Malenga, G; Matangila, J; Mavoko, M; Molyneux, M; Mukaka, M; Naw, HK; Nwakanma, D; Obonyo, C; Okebe, J; Onyamboko, M; Piola, P; Randremanana, R; Rwagacondo, C; Schramm, B; Sirima, SB; Taylor, WR; van Geertruyden, JP; White, NJ; Williams, TN; Yah, Z, 2018) |
| "Potentially untreatable Plasmodium falciparum malaria threatens the Greater Mekong subregion." | 1.48 | Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme. ( Delmas, G; Landier, J; Lwin, KM; Nosten, FH; Parker, DM; Thu, AM, 2018) |
| "The prevalence of G6PD deficiency in the Bamar, Karen and in the whole sample set was 6." | 1.43 | Validation of G6PD Point-of-Care Tests among Healthy Volunteers in Yangon, Myanmar. ( Bancone, G; Bansil, P; Chowwiwat, N; Domingo, GJ; Htun, MM; Htut, Y; Maw, LZ; Nosten, F; Oo, NN; Thant, KZ, 2016) |
| "1." | 1.43 | UK malaria treatment guidelines 2016. ( Beeching, NJ; Bell, DJ; Chiodini, PL; Lalloo, DG; Shingadia, D; Whitty, CJM, 2016) |
| "The Primaquine Roll Out Monitoring Pharmacovigilance Tool (PROMPT), comprising: (1) a standardized form to support the surveillance of possible adverse events following SLD PQ treatment; (2) a patient information card to enhance awareness of known adverse drug reactions of SLD PQ use; and (3) a database compiling recorded information, was developed and piloted." | 1.43 | Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study. ( Brown, J; Darteh, S; Gosling, R; Hwang, J; Kunene, S; Malambe, C; Maphalala, G; Mkhonta, N; Mwandemele, A; Ntshalintshali, N; Pace, C; Pan, S; Poirot, E; Soble, A; Stergachis, A; Vilakati, S; Vittinghoff, E, 2016) |
| "Upon primaquine treatment, elimination of gametocytes from peripheral blood and from sequestration sites was observed, providing a proof of concept that these mice can be used for testing drugs." | 1.43 | A humanized mouse model for sequestration of Plasmodium falciparum sexual stages and in vivo evaluation of gametocytidal drugs. ( Cisteró, P; Duffier, Y; Dupuy, F; Fiette, L; Jouvion, G; Lavazec, C; Lorthiois, A; Mayor, A; Mazier, D; Moreno Sabater, A, 2016) |
| " No dosing regimen was suggested, leaving malaria control programmes and clinicians in limbo." | 1.43 | An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia. ( Buchy, P; Chy, S; Debackere, M; Dondorp, AM; Fairhurst, RM; Kak, N; Kheang, ST; Kheng, S; Khu, NH; Leang, R; Menard, D; Mukaka, M; Muth, S; Ngak, S; Roca-Felterer, A; Tarantola, A; Taylor, WR; Tripura, R; White, NJ, 2016) |
| " Research is needed to define the therapeutic dose range, which will guide dosing regimens in the field, inform the development of new, lower strength primaquine tablets and/or formulation(s), and allay programmatic safety concerns in individuals with G6PD deficiency." | 1.42 | An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa. ( Chen, I; Cohen, JM; Gosling, R; Hwang, J; Kandula, D; Newman, M; Poirot, E; Rooney, L; Shah, R, 2015) |
| "The prevalence of G6PD deficiency by genotype and enzyme activity was determined in healthy school children in The Gambia." | 1.40 | The prevalence of glucose-6-phosphate dehydrogenase deficiency in Gambian school children. ( Affara, M; Amambua-Ngwa, A; Ceesay, SJ; D'Alessandro, U; Daswani, M; Nishimura, S; Nwakanma, D; Okebe, J; Parr, J; Takem, EN, 2014) |
| "vivax malaria is a substantial risk." | 1.40 | Imported malaria is stable from Africa but declining from Asia. ( David, K; Møller, CH, 2014) |
| " These data inform discussions on safe and effective primaquine dosing and future malaria elimination strategies for Haiti." | 1.40 | Glucose-6-phosphate dehydrogenase deficiency A- variant in febrile patients in Haiti. ( Carter, TE; Maloy, H; Mulligan, CJ; Okech, BA; Romain, JR; St Victor, Y; von Fricken, M, 2014) |
| "Falciparum malaria is transmitted by anopheline mosquitoes that have fed on blood containing gametocytes of Plasmodium falciparum." | 1.39 | Primaquine to prevent transmission of falciparum malaria. ( White, NJ, 2013) |
| "Primaquine is an old drug recently demonstrated to offer effective prophylaxis." | 1.32 | Primaquine for prevention of malaria in travelers. ( Baird, JK; Fryauff, DJ; Hoffman, SL, 2003) |
| "Pyronaridine was the most effective gametocytocidal drug against P." | 1.31 | Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro. ( Auparakkitanon, S; Chavalitshewinkoon-Petmitr, P; Pongvilairat, G; Wilairat, P, 2000) |
| "To assess the causal prophylactic activity (activity against the pre-erythrocytic liver stage) of a daily regimen of doxycycline combined with low dose primaquine against malaria in Australian Defence Force personnel deployed to Papua New Guinea (PNG)." | 1.29 | Effectiveness of doxycycline combined with primaquine for malaria prophylaxis. ( Barnett, A; Edstein, MD; Rieckmann, KH; Shanks, GD, 1995) |
| "Primaquine may also cause serious toxic side effects, including methaemoglobin formation and haemolytic anaemia, especially in individuals with erythrocyte glucose-6-phosphate dehydrogenase (G-6-PD) deficiency." | 1.29 | [Recurrence problems with preventive primaquine treatment in patients with malaria]. ( Bygbjerg, IC; Rønn, AM, 1993) |
| "2." | 1.29 | Interactions among primaquine, malaria infection and other antimalarials in Thai subjects. ( Davis, TM; Edwards, G; McGrath, CS; Pukrittayakamee, S; Supanaranond, W; Ward, SA; White, NJ, 1993) |
| "20 patients hemizygous for mild G6PD deficiency (GdB- variant), 2 patients hemizygous for severe deficiency (Gd-Myanmar variant) completed the trial." | 1.29 | The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar. ( , 1994) |
| "Quinine has been an effective drug for severe chloroquine-resistant falciparum malaria." | 1.28 | Plasma quinine levels in patients with falciparum malaria when given alone or in combination with tetracycline with or without primaquine. ( Bunnag, D; Harinasuta, T; Karbwang, J; Molunto, P, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.45) | 18.7374 |
| 1990's | 28 (13.53) | 18.2507 |
| 2000's | 40 (19.32) | 29.6817 |
| 2010's | 109 (52.66) | 24.3611 |
| 2020's | 27 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Huy, NT | 1 |
| Mizunuma, K | 1 |
| Kaur, K | 1 |
| Nhien, NT | 1 |
| Jain, M | 1 |
| Uyen, DT | 1 |
| Harada, S | 1 |
| Jain, R | 1 |
| Kamei, K | 1 |
| Flannery, EL | 1 |
| Fidock, DA | 1 |
| Winzeler, EA | 1 |
| Kannan, M | 1 |
| Raichurkar, AV | 1 |
| Khan, FR | 1 |
| Iyer, PS | 1 |
| McQueen, A | 1 |
| Blake, LD | 1 |
| Azhari, A | 1 |
| Kemp, MT | 1 |
| McGaha, TW | 1 |
| Namelikonda, N | 1 |
| Larsen, RW | 1 |
| Manetsch, R | 1 |
| Kyle, DE | 1 |
| Mosha, D | 3 |
| Kakolwa, MA | 1 |
| Mahende, MK | 1 |
| Masanja, H | 1 |
| Abdulla, S | 2 |
| Drakeley, C | 17 |
| Gosling, R | 15 |
| Wamoyi, J | 1 |
| van Beek, SW | 1 |
| Svensson, EM | 1 |
| Tiono, AB | 6 |
| Okebe, J | 7 |
| D'Alessandro, U | 7 |
| Gonçalves, BP | 6 |
| Bousema, T | 23 |
| Ter Heine, R | 1 |
| Poespoprodjo, JR | 2 |
| Burdam, FH | 1 |
| Candrawati, F | 1 |
| Ley, B | 6 |
| Meagher, N | 1 |
| Kenangalem, E | 1 |
| Indrawanti, R | 1 |
| Trianty, L | 1 |
| Thriemer, K | 5 |
| Price, DJ | 1 |
| Simpson, JA | 5 |
| Price, RN | 9 |
| Chotsiri, P | 1 |
| Mahamar, A | 4 |
| Hoglund, RM | 1 |
| Koita, F | 2 |
| Sanogo, K | 3 |
| Diawara, H | 4 |
| Dicko, A | 5 |
| White, NJ | 20 |
| Brown, JM | 5 |
| Chen, I | 7 |
| Tarning, J | 5 |
| Kaagaard, MD | 1 |
| Matos, LO | 1 |
| Holm, AE | 1 |
| Gomes, LC | 1 |
| Wegener, A | 1 |
| Lima, KO | 1 |
| Vieira, IVM | 1 |
| de Souza, RM | 1 |
| Marinho, CRF | 1 |
| Hviid, L | 1 |
| Vestergaard, LS | 1 |
| Dominguez, H | 1 |
| Biering-Sørensen, T | 1 |
| Silvestre, OM | 1 |
| Brainin, P | 1 |
| Alam, MS | 3 |
| Satyagraha, AW | 3 |
| Phru, CS | 1 |
| Tadesse, D | 1 |
| Shibiru, T | 1 |
| Hailu, A | 3 |
| Kibria, MG | 3 |
| Hossain, MS | 3 |
| Rahmat, H | 1 |
| Khan, WA | 1 |
| Degaga, TS | 2 |
| Christian, M | 2 |
| Tego, TT | 2 |
| Abate, DT | 2 |
| Weston, S | 2 |
| Karahalios, A | 2 |
| Rajasekhar, M | 2 |
| Rumaseb, A | 2 |
| Mnjala, H | 2 |
| Lee, G | 2 |
| Anose, RT | 2 |
| Kidane, FG | 1 |
| Woyessa, A | 2 |
| Baird, K | 1 |
| Sutanto, I | 3 |
| Stepniewska, K | 2 |
| Allen, EN | 1 |
| Humphreys, GS | 2 |
| Poirot, E | 6 |
| Craig, E | 2 |
| Kennon, K | 1 |
| Yilma, D | 1 |
| Guerin, PJ | 2 |
| Raman, J | 5 |
| Martensson, A | 5 |
| Mwaiswelo, RO | 2 |
| Bancone, G | 3 |
| Bastiaens, GJH | 3 |
| Bjorkman, A | 6 |
| Dicko, AA | 1 |
| El-Sayed, B | 2 |
| Elzaki, SE | 1 |
| Eziefula, AC | 8 |
| Hamid, MMA | 2 |
| Kaneko, A | 1 |
| Kariuki, S | 2 |
| Khan, W | 1 |
| Kwambai, TK | 2 |
| Ngasala, BE | 3 |
| Nosten, F | 5 |
| Samuels, AM | 2 |
| Smit, MR | 2 |
| Stone, WJR | 3 |
| Ter Kuile, F | 2 |
| Tine, RC | 2 |
| Drakeley, CJ | 3 |
| Stergachis, A | 2 |
| Barnes, KI | 5 |
| Ouologuem, DT | 1 |
| Dembele, L | 1 |
| Dara, A | 1 |
| Kone, AK | 1 |
| Diallo, N | 1 |
| Sangare, CPO | 1 |
| Ballo, FI | 1 |
| Dao, F | 1 |
| Goita, S | 1 |
| Haidara, AS | 1 |
| Traore, A | 1 |
| Niangaly, AB | 1 |
| Dama, S | 1 |
| Sissoko, S | 1 |
| Sogore, F | 1 |
| Dara, JN | 1 |
| Barre, YN | 1 |
| Daou, A | 1 |
| Cisse, F | 1 |
| Diakite, O | 1 |
| Doumbia, D | 1 |
| Koumare, S | 1 |
| Fofana, B | 1 |
| Tandina, F | 1 |
| Sylla, D | 1 |
| Sacko, A | 1 |
| Coulibaly, M | 1 |
| Tekete, MM | 1 |
| Ouattara, A | 1 |
| Djimde, AA | 1 |
| Taylor, WR | 6 |
| Olupot-Olupot, P | 4 |
| Onyamboko, MA | 4 |
| Peerawaranun, P | 4 |
| Weere, W | 3 |
| Namayanja, C | 4 |
| Onyas, P | 4 |
| Titin, H | 4 |
| Baseke, J | 4 |
| Muhindo, R | 4 |
| Kayembe, DK | 4 |
| Ndjowo, PO | 4 |
| Basara, BB | 4 |
| Bongo, GS | 3 |
| Okalebo, CB | 4 |
| Abongo, G | 3 |
| Uyoga, S | 4 |
| Williams, TN | 6 |
| Taya, C | 4 |
| Dhorda, M | 4 |
| Dondorp, AM | 8 |
| Waithira, N | 3 |
| Fanello, C | 5 |
| Maitland, K | 5 |
| Mukaka, M | 8 |
| Day, NJP | 3 |
| Morais, CMG | 1 |
| Brito, RMM | 1 |
| Weselucha-Birczyńska, A | 1 |
| Pereira, VSS | 1 |
| Pereira-Silva, JW | 1 |
| Menezes, A | 1 |
| Pessoa, FAC | 1 |
| Kucharska, M | 1 |
| Birczyńska-Zych, M | 1 |
| Ríos-Velásquez, CM | 1 |
| de Andrade-Neto, VF | 1 |
| Calit, J | 1 |
| Araújo, JE | 1 |
| Deng, B | 1 |
| Miura, K | 1 |
| Gaitán, XA | 1 |
| Araújo, MDS | 1 |
| Medeiros, JF | 1 |
| Long, CA | 1 |
| Simeonov, A | 1 |
| Eastman, RT | 1 |
| Bargieri, DY | 1 |
| Woon, SA | 1 |
| Moore, BR | 1 |
| Laman, M | 1 |
| Tesine, P | 1 |
| Lorry, L | 2 |
| Kasian, B | 1 |
| Yambo, P | 1 |
| Yadi, G | 1 |
| Pomat, W | 1 |
| Batty, KT | 1 |
| Salman, S | 1 |
| Robinson, LJ | 3 |
| Davis, TME | 1 |
| Manning, L | 1 |
| Sharma, S | 1 |
| Rawat, K | 1 |
| Bohidar, HB | 1 |
| Palombi, IR | 1 |
| Lawrence, N | 1 |
| White, AM | 1 |
| Gare, CL | 1 |
| Craik, DJ | 1 |
| McMorran, BJ | 1 |
| Malins, LR | 1 |
| Were, W | 1 |
| Bamisaiye, A | 1 |
| Day, NPJ | 4 |
| Taylor, WRJ | 1 |
| Sadhewa, A | 1 |
| Panggalo, LV | 1 |
| Ekawati, LL | 1 |
| Kiros, FG | 1 |
| Baird, JK | 11 |
| Pavić, K | 2 |
| Rubinić, B | 1 |
| Rajić, Z | 2 |
| Fontinha, D | 2 |
| Prudêncio, M | 2 |
| Uzelac, L | 3 |
| Kralj, M | 3 |
| Held, J | 2 |
| Zorc, B | 3 |
| Mendes Jorge, M | 1 |
| Ouermi, L | 1 |
| Meissner, P | 1 |
| Compaoré, G | 1 |
| Coulibaly, B | 1 |
| Nebie, E | 1 |
| Krisam, J | 1 |
| Klose, C | 1 |
| Kieser, M | 1 |
| Jahn, A | 1 |
| Lu, G | 1 |
| D Alessandro, U | 1 |
| Sié, A | 1 |
| Mockenhaupt, FP | 1 |
| Müller, O | 2 |
| Shekalaghe, S | 3 |
| Hamad, A | 1 |
| Mbaga, TA | 1 |
| Mihayo, M | 1 |
| Phommasone, K | 1 |
| van Leth, F | 1 |
| Peto, TJ | 1 |
| Landier, J | 2 |
| Nguyen, TN | 1 |
| Tripura, R | 2 |
| Pongvongsa, T | 1 |
| Lwin, KM | 2 |
| Kajeechiwa, L | 2 |
| Thwin, MM | 2 |
| Parker, DM | 2 |
| Wiladphaingern, J | 2 |
| Nosten, S | 2 |
| Proux, S | 1 |
| Nguon, C | 3 |
| Davoeung, C | 1 |
| Rekol, H | 3 |
| Adhikari, B | 1 |
| Promnarate, C | 1 |
| Chotivanich, K | 2 |
| Hanboonkunupakarn, B | 3 |
| Jittmala, P | 1 |
| Cheah, PY | 2 |
| Imwong, M | 3 |
| Pukrittayakamee, S | 4 |
| Newton, PN | 1 |
| Thwaites, GE | 2 |
| Mayxay, M | 1 |
| Hien, TT | 2 |
| Nosten, FH | 2 |
| Cobelens, F | 1 |
| von Seidlein, L | 4 |
| Chughlay, MF | 1 |
| Akakpo, S | 1 |
| Odedra, A | 1 |
| Csermak-Renner, K | 1 |
| Djeriou, E | 1 |
| Winnips, C | 1 |
| Leboulleux, D | 1 |
| Gaur, AH | 1 |
| Shanks, GD | 3 |
| McCarthy, J | 1 |
| Chalon, S | 2 |
| Mhamilawa, LE | 1 |
| Ngasala, B | 2 |
| Morris, U | 1 |
| Kitabi, EN | 1 |
| Barnes, R | 1 |
| Soe, AP | 1 |
| Mmbando, BP | 2 |
| Arroyo-Arroyo, MI | 1 |
| El-Sayed, BB | 1 |
| Elzaki, SG | 1 |
| Maestre, AE | 1 |
| Roh, ME | 2 |
| Sawa, P | 2 |
| Baker, L | 1 |
| Blaylock, M | 1 |
| Blumberg, L | 1 |
| Frean, J | 3 |
| Misiani, E | 1 |
| Ukpe, IS | 1 |
| Fernandez-Miñope, C | 1 |
| Delgado-Ratto, C | 1 |
| Contreras-Mancilla, J | 1 |
| Ferrucci, HR | 1 |
| Llanos-Cuentas, A | 1 |
| Gamboa, D | 1 |
| Van Geertruyden, JP | 3 |
| McLean, ARD | 1 |
| Indrasuta, C | 1 |
| Khant, ZS | 1 |
| Phyo, AK | 1 |
| Maung, SM | 1 |
| Heaton, J | 1 |
| Aung, H | 1 |
| Aung, Y | 1 |
| Soe, K | 1 |
| Swe, MMM | 1 |
| Tun, NN | 1 |
| Tun, KM | 1 |
| Ashley, EA | 3 |
| Hlaing, T | 1 |
| Kyaw, TT | 1 |
| Smithuis, FM | 1 |
| Jansongsaeng, S | 1 |
| Srimongkolpithak, N | 1 |
| Pengon, J | 1 |
| Kamchonwongpaisan, S | 1 |
| Khotavivattana, T | 1 |
| Briolant, S | 1 |
| Pradines, B | 1 |
| Basco, LK | 1 |
| Lin, JT | 1 |
| Lon, C | 2 |
| Spring, MD | 1 |
| Sok, S | 1 |
| Chann, S | 2 |
| Ittiverakul, M | 1 |
| Kuntawunginn, W | 2 |
| My, M | 1 |
| Thay, K | 1 |
| Rahman, R | 1 |
| Balasubramanian, S | 1 |
| Char, M | 1 |
| Lanteri, CA | 1 |
| Gosi, P | 2 |
| Ubalee, R | 1 |
| Meshnick, SR | 2 |
| Saunders, DL | 1 |
| Sylla, K | 1 |
| Faye, BT | 1 |
| Fall, FB | 1 |
| Sow, D | 1 |
| Wang, D | 1 |
| Ndiaye, M | 1 |
| Ndiaye, JL | 1 |
| Faye, B | 1 |
| Greenwood, B | 2 |
| Gaye, O | 2 |
| Milligan, P | 2 |
| Gebreyohannes, EA | 1 |
| Bhagavathula, AS | 1 |
| Seid, MA | 1 |
| Tegegn, HG | 1 |
| Tadesse, FG | 1 |
| Lanke, K | 4 |
| Nebie, I | 3 |
| Schildkraut, JA | 1 |
| Sauerwein, R | 4 |
| Rijpma, SR | 1 |
| Wampfler, R | 1 |
| Hofmann, NE | 1 |
| Karl, S | 1 |
| Betuela, I | 4 |
| Kinboro, B | 1 |
| Silkey, M | 1 |
| Mueller, I | 3 |
| Felger, I | 1 |
| Arroyo-Arroyo, M | 1 |
| Arango, E | 1 |
| Carmona-Fonseca, J | 2 |
| Aristizabal, B | 1 |
| Yanow, S | 1 |
| Maestre, A | 1 |
| Kumar, H | 1 |
| Gothwal, A | 1 |
| Khan, I | 1 |
| Nakhate, KT | 1 |
| Alexander, A | 1 |
| Singh, V | 2 |
| Gupta, U | 1 |
| Tickell-Painter, M | 1 |
| Maayan, N | 1 |
| Saunders, R | 1 |
| Pace, C | 2 |
| Sinclair, D | 1 |
| Baruah, UK | 1 |
| Gowthamarajan, K | 1 |
| Ravisankar, V | 1 |
| Karri, VVSR | 1 |
| Simhadri, PK | 1 |
| Babu, PP | 1 |
| Son, DH | 1 |
| Thuy-Nhien, N | 1 |
| Le Phuc-Nhi, T | 1 |
| Phu, NT | 1 |
| Tuyen, NTK | 1 |
| Tran, NH | 1 |
| Van Dung, N | 1 |
| Van Quan, B | 1 |
| Pett, HE | 1 |
| Coulibaly, SA | 1 |
| Affara, M | 4 |
| Ouédraogo, A | 2 |
| Bougouma, EC | 2 |
| Sanou, GS | 1 |
| Bradley, J | 5 |
| Lanke, KHW | 1 |
| Niemi, M | 2 |
| Sirima, SB | 3 |
| Naw, HK | 1 |
| Kapulu, M | 1 |
| Berkley, JA | 1 |
| Bejon, P | 1 |
| Achan, J | 1 |
| Amambua, AN | 1 |
| Nwakanma, D | 3 |
| Mavoko, M | 1 |
| Lutumba, P | 1 |
| Matangila, J | 1 |
| Brasseur, P | 2 |
| Piola, P | 1 |
| Randremanana, R | 1 |
| Lasry, E | 1 |
| Onyamboko, M | 1 |
| Schramm, B | 1 |
| Yah, Z | 1 |
| Jones, J | 1 |
| Fairhurst, RM | 2 |
| Diakite, M | 1 |
| Malenga, G | 1 |
| Molyneux, M | 1 |
| Rwagacondo, C | 1 |
| Obonyo, C | 1 |
| Gadisa, E | 1 |
| Aseffa, A | 1 |
| Loolpapit, M | 1 |
| Henry, MC | 1 |
| Dorsey, G | 1 |
| John, C | 1 |
| Kremsner, P | 1 |
| Day, NP | 4 |
| Rossi, G | 1 |
| Vernaeve, L | 1 |
| Van den Bergh, R | 1 |
| Debackere, M | 2 |
| Abello Peiri, C | 1 |
| Van, V | 1 |
| Khim, N | 3 |
| Kim, S | 3 |
| Eam, R | 1 |
| Ken, M | 1 |
| Khean, C | 1 |
| De Smet, M | 1 |
| Menard, D | 4 |
| Kindermans, JM | 1 |
| Collins, KA | 1 |
| Wang, CY | 1 |
| Adams, M | 1 |
| Mitchell, H | 1 |
| Rampton, M | 1 |
| Elliott, S | 1 |
| Reuling, IJ | 1 |
| Möhrle, JJ | 1 |
| McCarthy, JS | 1 |
| Graves, PM | 4 |
| Choi, L | 1 |
| Gelband, H | 4 |
| Garner, P | 4 |
| Levatić, J | 1 |
| Perković, I | 1 |
| Ester, K | 1 |
| Kaiser, M | 1 |
| Rottmann, M | 1 |
| Supek, F | 1 |
| Soumare, HM | 3 |
| Kone, DT | 1 |
| Diarra, K | 1 |
| Keita, S | 2 |
| Issiaka, D | 1 |
| Traore, SF | 2 |
| McCulloch, C | 2 |
| Hwang, J | 6 |
| Srinivasan, V | 1 |
| Cruz, M | 1 |
| Sánchez, IM | 1 |
| Diaz, J | 1 |
| Cuevas, F | 1 |
| Silva, M | 1 |
| Disla, M | 1 |
| Ferreira, PE | 2 |
| Veiga, MI | 2 |
| Elobied, ME | 1 |
| Mahgoub, NS | 1 |
| Boshara, SA | 1 |
| Elsafi, HMH | 1 |
| Gumaa, SA | 1 |
| Hamid, T | 1 |
| Abdelbagi, H | 1 |
| Basheir, HM | 1 |
| Marfurt, J | 1 |
| Awandu, SS | 1 |
| Makhanthisa, TI | 1 |
| Kruger, P | 1 |
| Niemand, J | 1 |
| Birkholtz, LM | 1 |
| Thu, AM | 1 |
| Delmas, G | 1 |
| Lover, AA | 1 |
| Deng, C | 2 |
| Huang, B | 1 |
| Wang, Q | 1 |
| Wu, W | 1 |
| Zheng, S | 1 |
| Zhang, H | 1 |
| Li, D | 1 |
| Feng, D | 1 |
| Li, G | 4 |
| Xue, L | 1 |
| Yang, T | 1 |
| Tuo, F | 1 |
| Mohadji, F | 1 |
| Su, XZ | 1 |
| Xu, Q | 1 |
| Wu, Z | 1 |
| Lin, L | 1 |
| Zhou, J | 1 |
| Yan, H | 1 |
| Bacar, A | 1 |
| Said Abdallah, K | 1 |
| Kéké, RA | 1 |
| Msa Mliva, A | 1 |
| Mohamed, M | 1 |
| Wang, X | 1 |
| Huang, S | 1 |
| Oithik, F | 1 |
| Li, XB | 1 |
| Lu, F | 1 |
| Fay, MP | 1 |
| Liu, XH | 1 |
| Wellems, TE | 2 |
| Song, J | 3 |
| Manning, J | 1 |
| Spring, M | 1 |
| Wojnarski, M | 1 |
| Somethy, S | 1 |
| Soveasna, K | 1 |
| Sriwichai, S | 1 |
| Fukuda, MM | 2 |
| Smith, PL | 1 |
| Sinoun, M | 1 |
| So, M | 1 |
| Lin, J | 1 |
| Satharath, P | 1 |
| Saunders, D | 1 |
| Avalos, S | 1 |
| Mejia, RE | 2 |
| Banegas, E | 2 |
| Salinas, C | 1 |
| Gutierrez, L | 1 |
| Fajardo, M | 1 |
| Galo, S | 1 |
| Pinto, A | 1 |
| Mejia, A | 1 |
| Fontecha, G | 2 |
| Roh, M | 1 |
| Delves, M | 1 |
| Churcher, TS | 2 |
| Dysoley, L | 1 |
| Lopes, S | 1 |
| Bjorges, S | 1 |
| Top, S | 2 |
| Huch, C | 1 |
| Westercamp, N | 1 |
| Roca-Feltrer, A | 1 |
| Allen, E | 1 |
| Workman, L | 1 |
| Mabuza, A | 1 |
| Swanepoel, H | 1 |
| Malatje, G | 1 |
| Wiesner, L | 1 |
| Camarda, G | 1 |
| Jirawatcharadech, P | 1 |
| Priestley, RS | 1 |
| Saif, A | 1 |
| March, S | 1 |
| Wong, MHL | 1 |
| Leung, S | 1 |
| Miller, AB | 1 |
| Baker, DA | 1 |
| Alano, P | 1 |
| Paine, MJI | 1 |
| Bhatia, SN | 1 |
| O'Neill, PM | 1 |
| Ward, SA | 3 |
| Biagini, GA | 1 |
| Beus, M | 1 |
| Shah, NK | 1 |
| Schapira, A | 1 |
| Juliano, JJ | 1 |
| Srivastava, B | 1 |
| MacDonald, PD | 1 |
| Poole, C | 1 |
| Anvikar, A | 1 |
| Valecha, N | 1 |
| Mishra, N | 1 |
| Howes, RE | 1 |
| Dewi, M | 1 |
| Piel, FB | 1 |
| Monteiro, WM | 1 |
| Battle, KE | 1 |
| Messina, JP | 1 |
| Sakuntabhai, A | 1 |
| Hay, SI | 1 |
| Yeung, S | 5 |
| Kamya, M | 1 |
| Owaraganise, A | 1 |
| Gabagaya, G | 1 |
| Grignard, L | 3 |
| Lanke, KH | 1 |
| Wanzira, H | 1 |
| Mpimbaza, A | 1 |
| Nsobya, S | 1 |
| Webb, EL | 1 |
| Staedke, SG | 2 |
| Steketee, RW | 1 |
| Abay, SM | 1 |
| Laothamatas, J | 1 |
| Sammet, CL | 1 |
| Golay, X | 1 |
| Van Cauteren, M | 1 |
| Lekprasert, V | 1 |
| Tangpukdee, N | 5 |
| Krudsood, S | 5 |
| Leowattana, W | 1 |
| Wilairatana, P | 6 |
| Swaminathan, SV | 1 |
| DeLaPaz, RL | 1 |
| Brown, TR | 1 |
| Looareesuwan, S | 4 |
| Brittenham, GM | 2 |
| Amambua-Ngwa, A | 1 |
| Parr, J | 1 |
| Nishimura, S | 1 |
| Daswani, M | 1 |
| Takem, EN | 1 |
| Ceesay, SJ | 1 |
| Møller, CH | 1 |
| David, K | 1 |
| Hetzel, MW | 1 |
| Page-Sharp, M | 1 |
| Bala, N | 1 |
| Pulford, J | 1 |
| Davis, TM | 3 |
| Lavu, EK | 1 |
| Meltzer, E | 2 |
| Schwartz, E | 2 |
| Goyal, K | 1 |
| Kaur, H | 1 |
| Sehgal, R | 1 |
| Carter, TE | 1 |
| Maloy, H | 1 |
| von Fricken, M | 1 |
| St Victor, Y | 1 |
| Romain, JR | 1 |
| Okech, BA | 1 |
| Mulligan, CJ | 1 |
| Pett, H | 4 |
| Opus, S | 1 |
| Kiggundu, M | 1 |
| Kamya, MR | 1 |
| Movellan, J | 1 |
| Urbán, P | 2 |
| Moles, E | 2 |
| de la Fuente, JM | 1 |
| Sierra, T | 1 |
| Serrano, JL | 1 |
| Fernàndez-Busquets, X | 2 |
| Dos-Santos, JC | 1 |
| Angerami, RN | 1 |
| Castiñeiras, CM | 1 |
| Lopes, SC | 1 |
| Albrecht, L | 1 |
| Garcia, MT | 1 |
| Levy, CE | 1 |
| Moretti, ML | 1 |
| Lacerda, MV | 1 |
| Costa, FT | 1 |
| Chen, IT | 1 |
| Gosling, RD | 1 |
| Lubell, Y | 1 |
| White, L | 1 |
| Varadan, S | 1 |
| Drake, T | 1 |
| Maude, RJ | 2 |
| Dondorp, A | 1 |
| Parker, M | 1 |
| Raccurt, CP | 1 |
| Lemoine, F | 1 |
| Cicéron, M | 1 |
| Existe, A | 1 |
| Boncy, J | 1 |
| Recht, J | 1 |
| Jittamala, P | 1 |
| Lee, SJ | 2 |
| Thana, P | 1 |
| Chairat, K | 1 |
| Blessborn, D | 1 |
| Panapipat, S | 1 |
| Gerardin, J | 1 |
| Eckhoff, P | 1 |
| Wenger, EA | 1 |
| Morrison, L | 1 |
| Stienlauf, S | 1 |
| Newman, M | 1 |
| Kandula, D | 1 |
| Shah, R | 1 |
| Cohen, JM | 1 |
| Rooney, L | 1 |
| Jiménez-Díaz, MB | 1 |
| Viera-Morilla, S | 1 |
| Angulo-Barturen, I | 1 |
| Busquets, MA | 1 |
| Rishikesh, K | 1 |
| Kamath, A | 1 |
| Hande, MH | 1 |
| Vidyasagar, S | 1 |
| Acharya, RV | 1 |
| Acharya, V | 1 |
| Belle, J | 1 |
| Shastry, AB | 1 |
| Saravu, K | 1 |
| Jacquerioz, FA | 2 |
| Croft, AM | 2 |
| Lalloo, DG | 1 |
| Shingadia, D | 2 |
| Bell, DJ | 1 |
| Beeching, NJ | 1 |
| Whitty, CJM | 1 |
| Chiodini, PL | 1 |
| Tine, R | 1 |
| Baber, I | 1 |
| Guelbéogo, WM | 1 |
| Siaka, D | 1 |
| Diarra, A | 1 |
| Chowwiwat, N | 2 |
| Somsakchaicharoen, R | 1 |
| Poodpanya, L | 1 |
| Moo, PK | 1 |
| Gornsawun, G | 1 |
| Rakthinthong, S | 1 |
| Thinraow, S | 1 |
| Nyo, SN | 1 |
| Ling, CL | 1 |
| Kiricharoen, NL | 1 |
| Moore, KA | 1 |
| Oo, NN | 1 |
| Maw, LZ | 1 |
| Bansil, P | 1 |
| Domingo, GJ | 1 |
| Htun, MM | 1 |
| Thant, KZ | 1 |
| Htut, Y | 1 |
| John, CC | 1 |
| Toyb, M | 1 |
| Ouledi, A | 1 |
| Gaüzère, BA | 1 |
| Aubry, P | 1 |
| Chang, HH | 1 |
| Meibalan, E | 1 |
| Zelin, J | 1 |
| Daniels, R | 1 |
| Meyer, EC | 1 |
| Tadesse, F | 1 |
| Joice, RC | 1 |
| Wirth, DF | 1 |
| Volkman, SK | 1 |
| Buckee, C | 1 |
| Marti, M | 1 |
| Atroosh, WM | 1 |
| Al-Mekhlafi, HM | 1 |
| Snounou, G | 1 |
| Al-Jasari, A | 1 |
| Sady, H | 1 |
| Nasr, NA | 1 |
| Lau, YL | 1 |
| Surin, J | 1 |
| Mwaiswelo, R | 2 |
| Jovel, I | 2 |
| Premji, Z | 2 |
| Kaewpruk, N | 1 |
| Tan-ariya, P | 1 |
| Sitthichot, N | 1 |
| Suwandittakul, N | 1 |
| Mungthin, M | 1 |
| Soble, A | 1 |
| Ntshalintshali, N | 1 |
| Mwandemele, A | 1 |
| Mkhonta, N | 1 |
| Malambe, C | 1 |
| Vilakati, S | 1 |
| Pan, S | 1 |
| Darteh, S | 1 |
| Maphalala, G | 1 |
| Brown, J | 1 |
| Vittinghoff, E | 1 |
| Kunene, S | 1 |
| Aydin-Schmidt, B | 1 |
| Mmbando, B | 1 |
| Duffier, Y | 1 |
| Lorthiois, A | 1 |
| Cisteró, P | 1 |
| Dupuy, F | 1 |
| Jouvion, G | 1 |
| Fiette, L | 1 |
| Mazier, D | 1 |
| Mayor, A | 1 |
| Lavazec, C | 1 |
| Moreno Sabater, A | 1 |
| Leang, R | 1 |
| Khu, NH | 1 |
| Kheang, ST | 1 |
| Chy, S | 1 |
| Kak, N | 1 |
| Buchy, P | 1 |
| Tarantola, A | 1 |
| Roca-Felterer, A | 1 |
| Kheng, S | 2 |
| Muth, S | 1 |
| Ngak, S | 1 |
| Di Tanna, GL | 1 |
| Dabira, E | 1 |
| Gaye, A | 1 |
| Sanya-Isijola, F | 1 |
| Badji, H | 1 |
| Correa, S | 1 |
| Thanachartwet, V | 1 |
| Pengruksa, C | 1 |
| Phophak, N | 1 |
| Kano, S | 2 |
| Lawpoolsri, S | 1 |
| Klein, EY | 1 |
| Singhasivanon, P | 1 |
| Yimsamran, S | 1 |
| Thanyavanich, N | 1 |
| Maneeboonyang, W | 1 |
| Hungerford, LL | 1 |
| Maguire, JH | 1 |
| Smith, DL | 1 |
| Daneshvar, C | 1 |
| Cox-Singh, J | 1 |
| Rafa'ee, MZ | 1 |
| Zakaria, SK | 1 |
| Divis, PC | 1 |
| Singh, B | 1 |
| Vásquez, AM | 1 |
| Sanín, F | 1 |
| Alvarez, LG | 1 |
| Tobón, A | 2 |
| Ríos, A | 2 |
| Blair, S | 2 |
| Chevalley, S | 1 |
| Coste, A | 1 |
| Lopez, A | 1 |
| Pipy, B | 1 |
| Valentin, A | 1 |
| Socheat, D | 2 |
| Tan, B | 1 |
| Dara, P | 2 |
| Sokunthea, S | 1 |
| Seila, S | 1 |
| Ou, F | 1 |
| Jian, H | 1 |
| Shekalaghe, SA | 1 |
| ter Braak, R | 1 |
| Daou, M | 1 |
| Kavishe, R | 1 |
| van den Bijllaardt, W | 1 |
| van den Bosch, S | 1 |
| Koenderink, JB | 1 |
| Luty, AJ | 1 |
| Whitty, CJ | 1 |
| Sauerwein, RW | 1 |
| Thapa, R | 1 |
| Ghosh, A | 1 |
| Mallick, D | 1 |
| Biswas, B | 1 |
| Okell, L | 1 |
| Griffin, JT | 2 |
| Omar, S | 1 |
| Sutherland, C | 1 |
| Ghani, AC | 2 |
| Alvarez, G | 1 |
| Piñeros, JG | 1 |
| Smithuis, F | 1 |
| Kyaw, MK | 1 |
| Phe, O | 1 |
| Win, T | 1 |
| Aung, PP | 1 |
| Oo, AP | 1 |
| Naing, AL | 1 |
| Nyo, MY | 1 |
| Myint, NZ | 1 |
| Ashley, E | 1 |
| Barber, BE | 1 |
| William, T | 1 |
| Jikal, M | 1 |
| Jilip, J | 1 |
| Dhararaj, P | 1 |
| Menon, J | 1 |
| Yeo, TW | 1 |
| Anstey, NM | 1 |
| Okell, LC | 1 |
| Kleinschmidt, I | 1 |
| Hollingsworth, TD | 1 |
| White, MJ | 1 |
| Kawai, A | 1 |
| Arita, N | 1 |
| Matsumoto, Y | 1 |
| Kawabata, M | 1 |
| Chowdhury, MS | 1 |
| Saito-Ito, A | 1 |
| Jovel, IT | 1 |
| Piedade, R | 1 |
| Alger, J | 1 |
| Enamorado, IG | 1 |
| Ursing, J | 1 |
| Arango, EM | 1 |
| Upegui, YA | 1 |
| Bassat, Q | 2 |
| Kiniboro, B | 2 |
| Rosanas-Urgell, A | 2 |
| Stanisic, D | 1 |
| Siba, PM | 1 |
| Alonso, PL | 2 |
| Kolaczinski, K | 1 |
| Leslie, T | 1 |
| Ali, I | 1 |
| Durrani, N | 1 |
| Lee, S | 1 |
| Barends, M | 1 |
| Beshir, K | 1 |
| Ord, R | 1 |
| Hallett, R | 1 |
| Rowland, M | 1 |
| Saroth, P | 1 |
| White, LJ | 1 |
| Stanisic, DI | 1 |
| Samol, L | 1 |
| de Lazzari, E | 1 |
| Del Portillo, HA | 1 |
| Siba, P | 1 |
| Kusriastuti, R | 1 |
| Surya, A | 1 |
| Hoyer, S | 1 |
| Nguon, S | 1 |
| Habib, N | 1 |
| Sum, S | 1 |
| Christophel, EM | 1 |
| Bjorge, S | 1 |
| Thomson, A | 1 |
| Chea, N | 1 |
| Yok, S | 1 |
| Ros, S | 1 |
| Sophal, U | 1 |
| Thompson, MM | 1 |
| Mellor, S | 1 |
| Ariey, F | 1 |
| Witkowski, B | 1 |
| Yeang, C | 1 |
| Duong, S | 1 |
| Newman, RD | 1 |
| Hsiang, MS | 1 |
| Kiang, KM | 1 |
| Bryant, PA | 1 |
| Ladhani, S | 1 |
| Steer, AC | 1 |
| Burgner, D | 1 |
| Qiao, LG | 1 |
| Qi, G | 1 |
| Luzzatto, L | 1 |
| Hung, le Q | 2 |
| Vries, PJ | 1 |
| Giao, PT | 2 |
| Nam, NV | 2 |
| Binh, TQ | 2 |
| Chong, MT | 1 |
| Quoc, NT | 1 |
| Thanh, TN | 1 |
| Hung, LN | 1 |
| Kager, PA | 3 |
| Wiady, I | 4 |
| Sutanihardja, A | 1 |
| Basri, H | 5 |
| Ayomi, E | 1 |
| Fryauff, DJ | 7 |
| Hoffman, SL | 6 |
| Huang, JR | 1 |
| Gao, YQ | 1 |
| Elie, N | 1 |
| Mehrunnisa, A | 1 |
| Saifi, MA | 1 |
| Khan, HM | 1 |
| Fernando, SD | 1 |
| Wickremasinghe, AR | 2 |
| Peters, W | 1 |
| Stewart, LB | 1 |
| Robinson, BL | 1 |
| Suputtamongkol, Y | 1 |
| Chindarat, S | 1 |
| Silpasakorn, S | 1 |
| Chaikachonpatd, S | 1 |
| Lim, K | 1 |
| Chanthapakajee, K | 1 |
| Kaewkaukul, N | 1 |
| Thamlikitkul, V | 1 |
| ARNOLD, J | 1 |
| ALVING, AS | 1 |
| HOCKWALD, RS | 1 |
| CLAYMAN, CB | 1 |
| DERN, RJ | 1 |
| BEUTLER, E | 1 |
| FLANAGAN, CL | 1 |
| JEFFERY, GM | 2 |
| YOUNG, MD | 1 |
| EYLES, DE | 1 |
| Miller, LH | 1 |
| de Vries, PJ | 1 |
| Chantra, A | 1 |
| Clemens, R | 2 |
| Rojanawatsirivej, C | 1 |
| Vijaykadga, S | 2 |
| Amklad, I | 1 |
| Wilairatna, P | 1 |
| Kamtekar, KD | 3 |
| Gogtay, NJ | 5 |
| Dalvi, SS | 3 |
| Karnad, DR | 1 |
| Chogle, AR | 4 |
| Aigal, U | 3 |
| Kshirsagar, NA | 4 |
| Rojanawatsirivet, C | 1 |
| Congpuong, K | 1 |
| Thongphua, S | 1 |
| Thongsri, K | 1 |
| Bangchang, KN | 2 |
| Wernsdorfer, WH | 1 |
| Singh, N | 1 |
| Mishra, AK | 1 |
| Shukla, MM | 1 |
| Chand, SK | 1 |
| Bharti, PK | 1 |
| Antinori, S | 1 |
| Morelli, P | 1 |
| Mehta, SS | 1 |
| Egan, TJ | 1 |
| Lederman, ER | 1 |
| Maguire, JD | 2 |
| Sumawinata, IW | 1 |
| Chand, K | 1 |
| Elyazar, I | 1 |
| Estiana, L | 1 |
| Sismadi, P | 2 |
| Bangs, MJ | 4 |
| Ndaro, A | 1 |
| van Meegeren, M | 1 |
| Enevold, A | 1 |
| Alifrangis, M | 1 |
| Mosha, F | 1 |
| El-Zaki, SE | 1 |
| Babiker, H | 1 |
| Gadalla, N | 1 |
| Ageep, T | 1 |
| Mansour, F | 1 |
| Baraka, O | 1 |
| Babiker, A | 1 |
| Sumawinata, I | 1 |
| Richie, TL | 4 |
| Ohrt, CK | 1 |
| Mouzin, E | 1 |
| Church, CJ | 1 |
| Richards, AL | 1 |
| Subianto, B | 3 |
| Leksana, B | 1 |
| Masbar, S | 1 |
| Barnett, A | 1 |
| Edstein, MD | 2 |
| Rieckmann, KH | 3 |
| Weiss, WR | 1 |
| Oloo, AJ | 1 |
| Johnson, A | 1 |
| Koech, D | 1 |
| Lazar, AI | 1 |
| Wilberschied, L | 1 |
| Karbwang, J | 3 |
| Thimasarn, K | 1 |
| Rooney, W | 1 |
| Bunnag, D | 3 |
| Harinasuta, T | 2 |
| Rønn, AM | 1 |
| Bygbjerg, IC | 1 |
| Edwards, G | 1 |
| McGrath, CS | 1 |
| Supanaranond, W | 1 |
| Weinke, T | 1 |
| Nothdurft, HD | 1 |
| Kretschmer, H | 1 |
| Fleischer, K | 1 |
| Löscher, T | 1 |
| Braendli, B | 1 |
| Markwalder, K | 1 |
| Schlunk, T | 1 |
| Bock, HL | 1 |
| Yeo, AE | 1 |
| Davis, DR | 1 |
| Hutton, DC | 1 |
| Wheatley, PF | 1 |
| Simpson, R | 1 |
| Patwari, AK | 1 |
| Awalludin, M | 1 |
| Jones, T | 1 |
| Tjitra, E | 2 |
| Wignall, FS | 1 |
| Harjosuwarno, S | 1 |
| Molez, JF | 1 |
| van der Hoek, W | 1 |
| Premasiri, DA | 1 |
| Zijlmans, CW | 1 |
| Boele van Hensbroek, M | 1 |
| Wetsteyn, JC | 1 |
| Soto, J | 2 |
| Toledo, J | 2 |
| Rodriquez, M | 2 |
| Sanchez, J | 2 |
| Herrera, R | 2 |
| Padilla, J | 2 |
| Berman, J | 2 |
| Menéndez Capote, RL | 1 |
| López Chávez, AU | 1 |
| Heppner, DG | 1 |
| Gasser, RA | 1 |
| Kester, KE | 1 |
| Juckett, G | 1 |
| Coley, TJ | 1 |
| Hart, JC | 1 |
| Botella de Maglia, J | 1 |
| Espacio Casanovas, A | 1 |
| Sorabjee, JS | 1 |
| Marathe, SN | 1 |
| Chavalitshewinkoon-Petmitr, P | 1 |
| Pongvilairat, G | 1 |
| Auparakkitanon, S | 1 |
| Wilairat, P | 1 |
| Carrasquilla, G | 1 |
| Banguero, M | 1 |
| Sanchez, P | 1 |
| Carvajal, F | 1 |
| Barker, RH | 1 |
| Gervais, GW | 1 |
| Algarin, E | 1 |
| Serrano, AE | 1 |
| Myrvang, B | 1 |
| Kramer, MH | 1 |
| Lobel, HO | 1 |
| Kumar, A | 1 |
| Kshrisagar, NA | 1 |
| Qing, HY | 1 |
| Kroeger, A | 1 |
| Kain, KC | 1 |
| Keystone, JS | 1 |
| Nicolas, X | 1 |
| Granier, H | 1 |
| Martin, J | 1 |
| Klotz, F | 1 |
| Walsh, DS | 1 |
| Eamsila, C | 1 |
| Sasiprapha, T | 1 |
| Nasveld, PE | 1 |
| Kitchener, S | 1 |
| Lacy, MD | 1 |
| Barcus, MJ | 1 |
| Gramzinski, R | 1 |
| Ling, J | 1 |
| Kusumaningsih, M | 1 |
| Jones, TR | 1 |
| Bourke, AT | 1 |
| Jankowski, EA | 1 |
| Owusu-Agyei, S | 1 |
| Binka, F | 1 |
| Koram, K | 1 |
| Anto, F | 1 |
| Adjuik, M | 1 |
| Nkrumah, F | 1 |
| Smith, T | 1 |
| Na Bangchang, K | 1 |
| Thanavibul, A | 1 |
| Back, DJ | 1 |
| Molunto, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)[NCT02787070] | Phase 4 | 420 participants (Actual) | Interventional | 2016-09-14 | Completed | ||
| The Malaria Heart Disease Study: A Novel Pathway to Subclinical Heart Disease[NCT04445103] | 597 participants (Actual) | Observational | 2020-06-21 | Terminated (stopped due to Due to the COVID-19 pandemic it was not possible to complete the study inclusion as originally anticipated.) | |||
| Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas - a Randomized Controlled Trial[NCT03916003] | Phase 4 | 500 participants (Actual) | Interventional | 2019-08-18 | Completed | ||
| Safety of Artesunate-amodiaquine Combined With Methylene Blue or Primaquine for Falciparum Malaria Treatment in African Children: A Randomised Controlled Trial[NCT02851108] | Phase 2 | 100 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| THE OPTIMAL TIMING OF PRIMAQUINE TO PREVENT MALARIA TRANSMISSION AFTER ARTEMISININ-COMBINATION THERAPY[NCT01906788] | Phase 4 | 250 participants (Anticipated) | Interventional | 2013-05-31 | Recruiting | ||
| "Aiming at Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in an Era of Imminent Plasmodium Falciparum Resistance in Bagamoyo District, Tanzania - New Strategies With Old Tools"[NCT03241901] | Phase 4 | 280 participants (Actual) | Interventional | 2017-07-27 | Completed | ||
| Targeted Chemo-elimination (TCE) to Eradicate Malaria in Areas of Suspected or Proven Artemisinin Resistance in Southeast Asia and South Asia[NCT01872702] | 8,000 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
| Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province[NCT02143934] | Phase 4 | 524 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Randomized, Placebo-controlled, Double-blind Trial Using Dihydroartemisinine+Piperaquine (DP) to Protect Forest Workers From Malaria in Bu Gia Map National Park[NCT02788864] | Phase 4 | 150 participants (Actual) | Interventional | 2016-05-20 | Completed | ||
| An Open-label Individually Randomised Controlled Trial to Assess the Efficacy of Artemether-lumefantrine Prophylaxis for Malaria Among Forest Goers in Cambodia[NCT04041973] | 1,480 participants (Actual) | Interventional | 2020-03-11 | Completed | |||
| Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia[NCT02654730] | Phase 2/Phase 3 | 61 participants (Actual) | Interventional | 2015-12-31 | Terminated (stopped due to Enrollment took longer than anticipated; it was financially and logistically impossible to recruit the final cohort (G6PDd 0.4mg/kg PQ).) | ||
| Evaluation of the Safety of Primaquine in Combination With Artemether-lumefantrine in Glucose-6-phosphate Dehydrogynase Deficient Males With an Asymptomatic Malaria Infection in Burkina Faso (SAFEPRIM)[NCT02174900] | Phase 2/Phase 3 | 70 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Blood Stage Challenge Study to Asses Mosquito Transmissibility in Participants Inoculated With Plasmodium Falciparum[NCT02431637] | Phase 1 | 6 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Proof-Of-Concept Study to Assess the Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent in Experimental P. Falciparum Infection[NCT02431650] | Phase 1/Phase 2 | 11 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Efficacy, Safety, and Pharmacokinetics of Sulphadoxine-pyrimethamine-amodiaquine (SP-AQ), SP-AQ Plus Primaquine, Dihydroartemisinin-piperaquine (DP), DP Plus Methylene Blue for Preventing Transmission of P. Falciparum Gametocytes in Mali[NCT02831023] | Phase 2 | 80 participants (Actual) | Interventional | 2016-07-31 | Completed | ||
| A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan[NCT02592408] | Phase 4 | 320 participants (Actual) | Interventional | 2015-11-30 | Completed | ||
| Does Artemisinin Combination Treatment Reduce the Radical Curative Efficacy of High Dose Tafenoquine for Plasmodium Vivax Malaria?[NCT05788094] | Phase 4 | 388 participants (Anticipated) | Interventional | 2023-06-26 | Recruiting | ||
| Targeting High-risk Populations With Enhanced Reactive Focal Mass Drug Administration: A Study to Assess the Effectiveness and Feasibility for Plasmodium Falciparum and Plasmodium Vivax Malaria in Thailand[NCT05052502] | 49,118 participants (Anticipated) | Interventional | 2020-11-01 | Recruiting | |||
| Targeting High-risk Populations With Enhanced Reactive Case Detection: a Study to Assess the Effectiveness and Feasibility for Reducing Plasmodium Falciparum and P. Vivax Malaria in Southern Lao Peoples Democratic Republic[NCT04416945] | 31,443 participants (Anticipated) | Interventional | 2020-09-20 | Recruiting | |||
| Defining Effective, Appropriate, Implementable Strategies for Malaria Elimination in Military Forces in Cambodia as a Model for Mobile Populations[NCT02653898] | Phase 4 | 1,050 participants (Actual) | Interventional | 2016-01-31 | Active, not recruiting | ||
| The Tolerability and Safety of Low Dose Primaquine for Transmission Blocking in Symptomatic Falciparum Infected Cambodians[NCT02434952] | Phase 4 | 109 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda[NCT01365598] | Phase 3 | 468 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Pyronaridine-Artesunate in Healthy Adult Subjects[NCT01552330] | Phase 1 | 17 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer[NCT02898779] | Phase 1 | 36 participants (Actual) | Interventional | 2017-05-01 | Completed | ||
| Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia[NCT01743820] | Phase 2 | 81 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of Low Dose Primaquine for Clearance of Gametocytes in Asymptomatic Individuals Infected With P. Falciparum in Burkina Faso[NCT01935882] | Phase 2/Phase 3 | 360 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Efficacy and Safety of a Single Low-dose Primaquine Added to Standard Artemether-lumefantrine Treatment for the Clearance of Plasmodium Falciparum Gametocytes.[NCT02090036] | Phase 4 | 220 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers Treated With Dihydroartemisinin-piperaquine in The Gambia[NCT01838902] | Phase 3 | 467 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine[NCT00509015] | 6,000 participants (Anticipated) | Interventional | 2008-02-29 | Completed | |||
| Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria[NCT00902811] | Phase 4 | 600 participants (Anticipated) | Interventional | 2008-12-31 | Recruiting | ||
| Pseudo-randomised, Double-blinded Placebo-controlled Trial of Chloroquine or Sulphadoxine-pyrimethamine Alone or in Combination With Primaquine or Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Pakistan[NCT00959517] | Phase 2 | 588 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Assessing the Effectiveness of Targeted Active Case Detection Among High Risk Populations in Southern Lao PDR[NCT03783299] | Phase 4 | 39,968 participants (Actual) | Interventional | 2017-11-28 | Completed | ||
| Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection[NCT02691910] | Phase 2/Phase 3 | 204 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan[NCT00330902] | Phase 3 | 104 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT01083095] | Early Phase 1 | 18 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers[NCT00367380] | Phase 2 | 18 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Phase 1 and Phase 2a Clinical Trial:Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites[NCT01082341] | Phase 1/Phase 2 | 27 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Haemoglobin concentrations will be measured in the field using a HemoCue® (HemoCue® AB, Angelholm, Sweden) (NCT02851108)
Timeframe: 7 days
| Intervention | g/dl (Mean) |
|---|---|
| AS-AQ-MB | 0.18 |
| AS-AQ-PQ | 0.54 |
Adverse events incidence (NCT02431637)
Timeframe: Blood stage Plasmodium falciparum Challenge Inoculum up to Day 31
| Intervention | Number of adverse events (Number) |
|---|---|
| Piperaquine Phosphate After Infected Blood Malaria Challenge | 40 |
Assessing the transmissibility by oocyst detection in mosquito midgut preparations following direct and membrane (indirect) feeding. (NCT02431650)
Timeframe: From day 10 to 21 post Piperaquine dosing
| Intervention | Participants (Count of Participants) |
|---|---|
| Primaquine 15mg | 2 |
| OZ439 500mg | 3 |
Adverse events incidence (NCT02431650)
Timeframe: From Challenge inoculum on day 0 until end of study on day 31
| Intervention | Number of adverse events (Number) |
|---|---|
| Primaquine 15mg | 17 |
| OZ439 500mg | 4 |
Thick blood smear was performed to patients daily on days 7 to 23, and every other day until day 29. Any prove of P. vivax infection was considered positive and confirmed later by real time polymerase chain reaction (rPCR). (NCT00367380)
Timeframe: Twenty eight days
| Intervention | days (Mean) |
|---|---|
| Group 1 | 11 |
| Group 2 | 11 |
| Group 3 | 9 |
29 reviews available for primaquine and Malaria, Falciparum
| Article | Year |
|---|---|
Using genetic methods to define the targets of compounds with antimalarial activity.
Topics: Animals; Anopheles; Antimalarials; Drug Resistance; Genetic Association Studies; Genome, Protozoan; | 2013 |
Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data.
Topics: Antimalarials; Artemisinins; Child; Child, Preschool; Glucosephosphate Dehydrogenase; Hemoglobins; H | 2022 |
Role of Nanomedicines in Controlling Malaria: A Review.
Topics: Animals; Antimalarials; Antiparasitic Agents; Female; Humans; Malaria; Malaria, Falciparum; Nanomedi | 2023 |
Advances and roadblocks in the treatment of malaria.
Topics: Antimalarials; Artemisinins; Drug Resistance; Drug Therapy, Combination; Humans; Malaria; Malaria, F | 2022 |
Efficacy of Single-Dose Primaquine With Artemisinin Combination Therapy on Plasmodium falciparum Gametocytes and Transmission: An Individual Patient Meta-Analysis.
Topics: Animals; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artemisinins; Humans; | 2022 |
[Role of primaquine in malaria control and elimination in French-speaking Africa].
Topics: Africa; Africa, Northern; Disease Eradication; Humans; Infection Control; Language; Malaria, Falcipa | 2017 |
Anti-malarial treatment outcomes in Ethiopia: a systematic review and meta-analysis.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chloroquine; Drug Combinatio | 2017 |
Mefloquine for preventing malaria during travel to endemic areas.
Topics: Adult; Antimalarials; Atovaquone; Child; Chloroquine; Doxycycline; Drug Combinations; Drug Resistanc | 2017 |
Primaquine or other 8-aminoquinolines for reducing Plasmodium falciparum transmission.
Topics: Adult; Antimalarials; Artemisinins; Child; Chloroquine; Drug Combinations; Glucosephosphate Dehydrog | 2018 |
Malaria Elimination: Time to Target All Species.
Topics: Animals; Anopheles; Antimalarials; Chloroquine; Disease Eradication; Host-Parasite Interactions; Hum | 2018 |
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi | 2013 |
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi | 2013 |
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi | 2013 |
Spatial distribution of G6PD deficiency variants across malaria-endemic regions.
Topics: Antimalarials; Gene Frequency; Genetic Variation; Global Health; Glucosephosphate Dehydrogenase Defi | 2013 |
Blocking malaria transmission to Anopheles mosquitoes using artemisinin derivatives and primaquine: a systematic review and meta-analysis.
Topics: Animals; Anopheles; Antimalarials; Artemisinins; Humans; Malaria, Falciparum; Plasmodium falciparum; | 2013 |
Primaquine or other 8-aminoquinoline for reducing P. falciparum transmission.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Combinations; Glucosephosphate Dehydrogen | 2014 |
Primaquine: the risks and the benefits.
Topics: Antimalarials; Glucosephosphate Dehydrogenase Deficiency; Hemolysis; Humans; Malaria, Falciparum; Pr | 2014 |
Primaquine or other 8-aminoquinoline for reducing Plasmodium falciparum transmission.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Combinations; Glucosephosphate Dehydrogen | 2015 |
WITHDRAWN: Drugs for preventing malaria in travellers.
Topics: Adult; Antimalarials; Atovaquone; Child; Chloroquine; Doxycycline; Drug Combinations; Drug Resistanc | 2015 |
Drugs for preventing malaria in travellers.
Topics: Adult; Antimalarials; Atovaquone; Child; Chloroquine; Doxycycline; Drug Combinations; Drug Resistanc | 2009 |
Long term primaquine administration to reduce Plasmodium falciparum gametocyte transmission in hypoendemic areas.
Topics: Animals; Antimalarials; Carrier State; Drug Administration Schedule; Drug Therapy, Combination; Germ | 2010 |
Primaquine for reducing Plasmodium falciparum transmission.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Drug Combinations; Glucosephosphate Dehydrogen | 2012 |
Rationale for short course primaquine in Africa to interrupt malaria transmission.
Topics: Africa; Antimalarials; Clinical Trials as Topic; Disease Transmission, Infectious; Humans; London; M | 2012 |
The treatment of imported malaria in children: an update.
Topics: Administration, Intravenous; Administration, Oral; Adult; Antimalarials; Artemisinins; Child; Drug T | 2013 |
Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common.
Topics: Adult; Anemia, Hemolytic; Animals; Anopheles; Antimalarials; Artemisinins; Drug Therapy, Combination | 2012 |
[The treatment of malaria].
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Female; Humans; Infant, Newborn; Malar | 1997 |
Malaria prevention in travelers.
Topics: Animals; Antimalarials; Bedding and Linens; Chloroquine; Doxycycline; Humans; Malaria; Malaria, Falc | 1999 |
[Malaria in Norway--diagnosis, treatment and prevention].
Topics: Antimalarials; Chloroquine; Humans; Insect Bites and Stings; Malaria; Malaria, Falciparum; Mefloquin | 2000 |
Antimalarial chemoprophylaxis in infants and children.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Doxycycline; Humans; Infant; Malaria, Falciparu | 2001 |
Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens.
Topics: Animals; Antimalarials; Atovaquone; Azithromycin; Chloroquine; Drug Resistance; Health Planning Guid | 2001 |
[Epidemiological and therapeutic aspects of plasmodial infection from Plasmodium vivax].
Topics: Antimalarials; Chloroquine; Clinical Protocols; Drug Resistance; Drug Therapy, Combination; Humans; | 2000 |
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Hu | 2001 |
66 trials available for primaquine and Malaria, Falciparum
| Article | Year |
|---|---|
Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial.
Topics: Antimalarials; Australia; Humans; Indonesia; Infant; Malaria, Falciparum; Malaria, Vivax; Primaquine | 2022 |
Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areas-a randomized controlled trial (PRIMA).
Topics: Antimalarials; Hemoglobinuria; Humans; Malaria; Malaria, Falciparum; Malaria, Vivax; Male; Plasmodiu | 2022 |
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, n
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Democratic Republic of | 2023 |
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, n
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Democratic Republic of | 2023 |
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, n
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Democratic Republic of | 2023 |
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, n
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Democratic Republic of | 2023 |
Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Humans; Malaria; Malari | 2023 |
Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low-dose primaquine or placebo.
Topics: alpha-Thalassemia; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Child; Chil | 2023 |
Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Australia; Humans; Malaria; Ma | 2023 |
Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Burkina Faso; Child, Preschool; Drug Therapy, | 2019 |
Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether-lumefantrine.
Topics: Adolescent; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Carrier State; C | 2020 |
Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Cambodia; Child; Female; Humans; Malaria, Falciparum | 2020 |
Parasite clearance, cure rate, post-treatment prophylaxis and safety of standard 3-day versus an extended 6-day treatment of artemether-lumefantrine and a single low-dose primaquine for uncomplicated Plasmodium falciparum malaria in Bagamoyo district, Tan
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Child; Child, Preschool | 2020 |
Mass drug administration for the acceleration of malaria elimination in a region of Myanmar with artemisinin-resistant falciparum malaria: a cluster-randomised trial.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Cluster Analysis; Disease Eradication; Drug R | 2021 |
Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial.
Topics: Adolescent; Adult; Animals; Anopheles; Antimalarials; Artemisinins; Dose-Response Relationship, Drug | 2017 |
Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial.
Topics: Adolescent; Adult; Aged; Antimalarials; Female; Hemoglobins; Humans; Malaria, Falciparum; Male; Midd | 2017 |
Molecular Markers for Sensitive Detection of
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Biomarkers; Burkina Faso; DN | 2017 |
Effects of liver-stage clearance by Primaquine on gametocyte carriage of Plasmodium vivax and P. falciparum.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Blood; Child; Child, Prescho | 2017 |
Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials.
Topics: Adult; Antimalarials; Burkina Faso; Glucosephosphate Dehydrogenase; Humans; Malaria, Falciparum; Mal | 2018 |
Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials.
Topics: Adult; Antimalarials; Burkina Faso; Glucosephosphate Dehydrogenase; Humans; Malaria, Falciparum; Mal | 2018 |
Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials.
Topics: Adult; Antimalarials; Burkina Faso; Glucosephosphate Dehydrogenase; Humans; Malaria, Falciparum; Mal | 2018 |
Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials.
Topics: Adult; Antimalarials; Burkina Faso; Glucosephosphate Dehydrogenase; Humans; Malaria, Falciparum; Mal | 2018 |
A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.
Topics: Adamantane; Adolescent; Adult; Animals; Antimalarials; Culicidae; Erythrocytes; Female; Humans; Mala | 2018 |
A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.
Topics: Adamantane; Adolescent; Adult; Animals; Antimalarials; Culicidae; Erythrocytes; Female; Humans; Mala | 2018 |
A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.
Topics: Adamantane; Adolescent; Adult; Animals; Antimalarials; Culicidae; Erythrocytes; Female; Humans; Mala | 2018 |
A controlled human malaria infection model enabling evaluation of transmission-blocking interventions.
Topics: Adamantane; Adolescent; Adult; Animals; Antimalarials; Culicidae; Erythrocytes; Female; Humans; Mala | 2018 |
Efficacy and safety of primaquine and methylene blue for prevention of Plasmodium falciparum transmission in Mali: a phase 2, single-blind, randomised controlled trial.
Topics: Adolescent; Adult; Amodiaquine; Artemisinins; Child; Child, Preschool; Drug Combinations; Humans; Ma | 2018 |
Low risk of recurrence following artesunate-Sulphadoxine-pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Female; Humans; Infant; Inf | 2018 |
Cluster-randomized trial of monthly malaria prophylaxis versus focused screening and treatment: a study protocol to define malaria elimination strategies in Cambodia.
Topics: Adolescent; Adult; Aged; Antimalarials; Artemisinins; Cambodia; Child; Child, Preschool; Disease Era | 2018 |
Transmission-blocking Effects of Primaquine and Methylene Blue Suggest Plasmodium falciparum Gametocyte Sterilization Rather Than Effects on Sex Ratio.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Culicidae; Female; Humans; Malar | 2019 |
The tolerability of single low dose primaquine in glucose-6-phosphate deficient and normal falciparum-infected Cambodians.
Topics: Adolescent; Adult; Aged; Antimalarials; Artemisinins; Cambodia; Child; Child, Preschool; Female; Glu | 2019 |
Safety and tolerability of single low-dose primaquine in a low-intensity transmission area in South Africa: an open-label, randomized controlled trial.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Cytochrome P-450 CYP2D6; Female; Ge | 2019 |
Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinations; Drug The | 2013 |
Single dose primaquine for clearance of Plasmodium falciparum gametocytes in children with uncomplicated malaria in Uganda: a randomised, controlled, double-blind, dose-ranging trial.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, Preschool; Dos | 2014 |
Glucose-6-phosphate dehydrogenase status and risk of hemolysis in Plasmodium falciparum-infected African children receiving single-dose primaquine.
Topics: Antimalarials; Child; Child, Preschool; Double-Blind Method; Drug Administration Schedule; Female; G | 2014 |
Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects.
Topics: Administration, Oral; Adult; Antimalarials; Artemisinins; Artesunate; Cross-Over Studies; Drug Inter | 2015 |
Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial.
Topics: Animals; Anopheles; Antimalarials; Artemisinins; Drug Administration Schedule; Drug Therapy, Combina | 2016 |
Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial.
Topics: Antimalarials; Artemether; Artemisinins; Asymptomatic Infections; Child; Child, Preschool; Double-Bl | 2016 |
Single Low Dose Primaquine (0.25 mg/kg) Does Not Cause Clinically Significant Haemolysis in G6PD Deficient Subjects.
Topics: Adult; Antimalarials; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Glucosephos | 2016 |
Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemether, Lumefantrine Drug Combination | 2016 |
Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemether, Lumefantrine Drug Combination | 2016 |
Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemether, Lumefantrine Drug Combination | 2016 |
Safety of a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen for treatment of acute uncomplicated Plasmodium falciparum malaria in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemether, Lumefantrine Drug Combination | 2016 |
Adding a single low-dose of primaquine (0.25 mg/kg) to artemether-lumefantrine did not compromise treatment outcome of uncomplicated Plasmodium falciparum malaria in Tanzania: a randomized, single-blinded clinical trial.
Topics: Adolescent; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; Child, Pr | 2016 |
The Gametocytocidal Efficacy of Different Single Doses of Primaquine with Dihydroartemisinin-piperaquine in Asymptomatic Parasite Carriers in The Gambia: A Randomized Controlled Trial.
Topics: Adolescent; Antimalarials; Artemisinins; Asymptomatic Diseases; Carrier State; Child; Drug Therapy, | 2016 |
Efficacy of Artequick versus artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria in Thailand.
Topics: Acute Disease; Adolescent; Adult; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Female | 2008 |
[Therapeutic efficacy of a regimen of artesunate-mefloquine-primaquine treatment for Plasmodium falciparum malaria and treatment effects on gametocytic development].
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Child; Drug Resistance; Drug Th | 2009 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A-) individuals.
Topics: Anemia; Anti-Infective Agents; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Dru | 2010 |
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr | 2010 |
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr | 2010 |
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr | 2010 |
Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Child; Child, Preschool; Dr | 2010 |
Efficacy of different primaquine-based antimalarial regimens against Plasmodium falciparum gametocytemia.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2012 |
Defining Plasmodium falciparum treatment in South West Asia: a randomized trial comparing artesunate or primaquine combined with chloroquine or SP.
Topics: Adolescent; Antimalarials; Artemisinins; Artesunate; Child; Chloroquine; Drug Combinations; Drug Res | 2012 |
Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age.
Topics: Antimalarials; Artemisinins; Artesunate; Child, Preschool; Drug Therapy, Combination; Female; Humans | 2012 |
Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia.
Topics: Antimalarials; Chloroquine; Drug Therapy, Combination; Humans; Incidence; Indonesia; Malaria, Falcip | 2002 |
[A study of artemether combined with primaquine in the treatment of falciparum malaria].
Topics: Adolescent; Adult; Antimalarials; Artemether; Artemisinins; Child; Drug Therapy, Combination; Female | 2001 |
The efficacy of combined mefloquine-artesunate versus mefloquine-primaquine on subsequent development of Plasmodium falciparum gametocytemia.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Drug Resi | 2003 |
CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Atovaquone; Drug Combinations; Drug T | 2004 |
Activities of artesunate and primaquine against asexual- and sexual-stage parasites in falciparum malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Artesunate; Drug Therapy, Combination; Eryt | 2004 |
Monitoring the therapeutic efficacy of antimalarials against uncomplicated falciparum malaria in Thailand.
Topics: Adolescent; Adult; Aged; Antimalarials; Artemether; Artemisinins; Artesunate; Child; Drug Resistance | 2003 |
A prospective study evaluating the efficacy of a single, 45-mg dose of primaquine, as a gametocytocidal agent, in patients with Plasmodium falciparum malaria in Mumbai, India.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Drug Administration Schedule; Drug Therapy, Com | 2004 |
Preliminary report of the evaluation of the gametocytocidal action of bulaquine, in adult patients with acute, Plasmodium falciparum malaria.
Topics: Acute Disease; Adult; Animals; Antimalarials; Drug Therapy, Combination; Humans; Malaria, Falciparum | 2004 |
A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide-responsive uncomplicated falciparum malaria [ISCRTN50134587].
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Doxycycline; Drug Administration Schedule; Drug The | 2006 |
Combined chloroquine, sulfadoxine/pyrimethamine and primaquine against Plasmodium falciparum in Central Java, Indonesia.
Topics: Adolescent; Adult; Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Therapy, Combination | 2006 |
Primaquine clears submicroscopic Plasmodium falciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate.
Topics: Adolescent; Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinat | 2007 |
A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Chi | 2007 |
A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Chi | 2007 |
A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Chi | 2007 |
A randomized open-label trial of artesunate- sulfadoxine-pyrimethamine with or without primaquine for elimination of sub-microscopic P. falciparum parasitaemia and gametocyte carriage in eastern Sudan.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Chi | 2007 |
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu | 1995 |
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu | 1995 |
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu | 1995 |
Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria.
Topics: Adolescent; Adult; Antimalarials; Chloroquine; Double-Blind Method; Drug Administration Schedule; Hu | 1995 |
Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia.
Topics: Adolescent; Adult; Animals; Anopheles; Child; Chloroquine; Confounding Factors, Epidemiologic; Drug | 1995 |
Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil.
Topics: Adolescent; Child; Chloroquine; Doxycycline; Drug Administration Schedule; Humans; Kenya; Malaria, F | 1995 |
[Halofantrine in the treatment of imported malaria in nonimmune travelers].
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Drug Therapy, Combination; Drug Tolerance; Female; | 1993 |
Recent military experience with malaria chemoprophylaxis.
Topics: Antimalarials; Australia; Chloroquine; Dapsone; Doxycycline; Drug Administration Schedule; Drug Comb | 1993 |
Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis.
Topics: Antimalarials; Chloroquine; Disease Susceptibility; Follow-Up Studies; Humans; Incidence; Indonesia; | 1997 |
Halofantrine and primaquine for radical cure of malaria in Irian Jaya, Indonesia.
Topics: Adult; Antimalarials; Chloroquine; Drug Therapy, Combination; Follow-Up Studies; Humans; Indonesia; | 1997 |
Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Antimalarials; Colombia; Double-Blind Method; Gastrointestinal Diseases; Humans; | 1998 |
Double-blind, randomized, placebo-controlled assessment of chloroquine/primaquine prophylaxis for malaria in nonimmune Colombian soldiers.
Topics: Antimalarials; Chloroquine; Colombia; Double-Blind Method; Humans; Malaria; Malaria, Falciparum; Mal | 1999 |
Poor gametocytocidal activity of 45 mg primaquine in chloroquine-treated patients with acute, uncomplicated, Plasmodium falciparum malaria in Mumbai (Bombay): an issue of public-health importance.
Topics: Animals; Antimalarials; Chloroquine; Double-Blind Method; Drug Resistance; Drug Therapy, Combination | 1999 |
Malaria prophylaxis/radical cure: recent experiences of the Australian Defence Force.
Topics: Aminoquinolines; Antimalarials; Australia; Controlled Clinical Trials as Topic; Endemic Diseases; Hu | 2001 |
Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia.
Topics: Adolescent; Adult; Animals; Antimalarials; Atovaquone; Chemoprevention; Child; Drug Combinations; Fe | 2001 |
Does radical cure of asymptomatic Plasmodium falciparum place adults in endemic areas at increased risk of recurrent symptomatic malaria?
Topics: Adolescent; Adult; Antimalarials; Cohort Studies; Doxycycline; Drug Administration Schedule; Drug Th | 2002 |
Pharmacokinetics of mefloquine in the presence of primaquine.
Topics: Adult; Animals; Diarrhea; Drug Interactions; Humans; Malaria, Falciparum; Male; Mefloquine; Middle A | 1992 |
113 other studies available for primaquine and Malaria, Falciparum
| Article | Year |
|---|---|
2-tert-butyl-8-quinolinamines exhibit potent blood schizontocidal antimalarial activity via inhibition of heme crystallization.
Topics: Animals; Antimalarials; Erythrocytes; Hemeproteins; Hemolysis; Humans; Malaria, Falciparum; Parasiti | 2007 |
Synthesis and in vitro evaluation of novel 8-aminoquinoline-pyrazolopyrimidine hybrids as potent antimalarial agents.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Falciparum; Molecular Docking Simulation; Parasitic | 2015 |
Synthesis, characterization, and cellular localization of a fluorescent probe of the antimalarial 8-aminoquinoline primaquine.
Topics: Aminoquinolines; Antimalarials; Erythrocytes; Fluorescent Dyes; Hep G2 Cells; Humans; Life Cycle Sta | 2017 |
Safety monitoring experience of single-low dose primaquine co-administered with artemether-lumefantrine among providers and patients in routine healthcare practice: a qualitative study in Eastern Tanzania.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Child; Cross-Sectional Studies; Fem | 2021 |
Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa.
Topics: Adolescent; Adult; Africa South of the Sahara; Antimalarials; Child; Child, Preschool; Drug Combinat | 2021 |
Mechanistic Modeling of Primaquine Pharmacokinetics, Gametocytocidal Activity, and Mosquito Infectivity.
Topics: Animals; Antimalarials; Artemisinins; Culicidae; Drug Therapy, Combination; Humans; Malaria, Falcipa | 2022 |
Frequency of Electrocardiographic Alterations and Pericardial Effusion in Patients With Uncomplicated Malaria.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Brazil; Case-Control Studies; Chlor | 2022 |
Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria.
Topics: Antimalarials; Cross-Sectional Studies; Glucosephosphate Dehydrogenase; Glucosephosphate Dehydrogena | 2022 |
A Novel
Topics: Antimalarials; Chloroquine; Humans; Malaria, Falciparum; Plasmodium falciparum; Primaquine | 2022 |
Blood-stage antiplasmodial activity and oocyst formation-blockage of metallo copper-cinchonine complex.
Topics: Animals; Antimalarials; Chloroquine; Copper; Malaria, Falciparum; Malaria, Vivax; Mice; Oocysts; Par | 2022 |
Novel Transmission-Blocking Antimalarials Identified by High-Throughput Screening of Plasmodium berghei Ookluc.
Topics: Animals; Antimalarials; Culicidae; High-Throughput Screening Assays; Humans; Malaria; Malaria, Falci | 2023 |
Development of Antiplasmodial Peptide-Drug Conjugates Using a Human Protein-Derived Cell-Penetrating Peptide with Selectivity for Infected Cells.
Topics: Antimalarials; Cell-Penetrating Peptides; Humans; Malaria; Malaria, Falciparum; Pharmaceutical Prepa | 2023 |
Primaquine homodimers as potential antiplasmodial and anticancer agents.
Topics: Antimalarials; Antineoplastic Agents; Humans; Malaria, Falciparum; Molecular Structure; Neoplasms; P | 2019 |
Liver Enzyme Elevations in
Topics: Acrylamides; Adamantane; Adult; Alanine Transaminase; Aminopyridines; Aminoquinolines; Antimalarials | 2020 |
Maintaining focus on administering effective malaria treatment during the COVID-19 pandemic.
Topics: Administration, Intravenous; Antigens, Protozoan; Antimalarials; Artemether, Lumefantrine Drug Combi | 2020 |
Towards one standard treatment for uncomplicated Plasmodium falciparum and Plasmodium vivax malaria: Perspectives from and for the Peruvian Amazon.
Topics: Adult; Aminoquinolines; Artemisinins; Female; Humans; Malaria, Falciparum; Malaria, Vivax; Peru; Pla | 2021 |
5-Phenoxy Primaquine Analogs and the Tetraoxane Hybrid as Antimalarial Agents.
Topics: Adult; Antimalarials; Erythrocytes; Female; Humans; Malaria, Falciparum; Male; Middle Aged; Plasmodi | 2021 |
Efficacy of Different Primaquine Regimens to Control
Topics: Adolescent; Adult; Artemether, Lumefantrine Drug Combination; Artemisinins; Colombia; Drug Administr | 2017 |
Galactose-Anchored Gelatin Nanoparticles for Primaquine Delivery and Improved Pharmacokinetics: A Biodegradable and Safe Approach for Effective Antiplasmodial Activity against P. falciparum 3D7 and in Vivo Hepatocyte Targeting.
Topics: Animals; Antimalarials; Biological Availability; Delayed-Action Preparations; Drug Design; Drug Libe | 2017 |
Design, characterization and antimalarial efficacy of PEGylated galactosylated nano lipid carriers of primaquine phosphate.
Topics: Animals; Antimalarials; Drug Carriers; Humans; Lipids; Malaria, Falciparum; Mice; Nanoparticles; Pla | 2018 |
The prevalence, incidence and prevention of Plasmodium falciparum infections in forest rangers in Bu Gia Map National Park, Binh Phuoc province, Vietnam: a pilot study.
Topics: Adult; Antibiotic Prophylaxis; Antimalarials; Artemisinins; Drug Therapy, Combination; Feasibility S | 2017 |
The prevalence, incidence and prevention of Plasmodium falciparum infections in forest rangers in Bu Gia Map National Park, Binh Phuoc province, Vietnam: a pilot study.
Topics: Adult; Antibiotic Prophylaxis; Antimalarials; Artemisinins; Drug Therapy, Combination; Feasibility S | 2017 |
The prevalence, incidence and prevention of Plasmodium falciparum infections in forest rangers in Bu Gia Map National Park, Binh Phuoc province, Vietnam: a pilot study.
Topics: Adult; Antibiotic Prophylaxis; Antimalarials; Artemisinins; Drug Therapy, Combination; Feasibility S | 2017 |
The prevalence, incidence and prevention of Plasmodium falciparum infections in forest rangers in Bu Gia Map National Park, Binh Phuoc province, Vietnam: a pilot study.
Topics: Adult; Antibiotic Prophylaxis; Antimalarials; Artemisinins; Drug Therapy, Combination; Feasibility S | 2017 |
Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa.
Topics: Adolescent; Adult; Africa South of the Sahara; Age Factors; Aged; Aged, 80 and over; Antimalarials; | 2018 |
Closing in on the Reservoir: Proactive Case Detection in High-Risk Groups as a Strategy to Detect Plasmodium falciparum Asymptomatic Carriers in Cambodia.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Cambodia; Carrier State; Child; Child, Preschool; Di | 2018 |
Machine learning prioritizes synthesis of primaquine ureidoamides with high antimalarial activity and attenuated cytotoxicity.
Topics: Amides; Animals; Antimalarials; Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response | 2018 |
Drugs that reduce transmission of falciparum malaria.
Topics: Humans; Malaria, Falciparum; Mali; Methylene Blue; Plasmodium falciparum; Primaquine; Single-Blind M | 2018 |
Dosage of Single Low-Dose Primaquine to Stop Malaria Transmission.
Topics: Antimalarials; Humans; Malaria, Falciparum; Plasmodium falciparum; Primaquine | 2018 |
Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Female; Gene Expression Regulat | 2018 |
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2018 |
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2018 |
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2018 |
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2018 |
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2018 |
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2018 |
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2018 |
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2018 |
Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2018 |
Large-scale Artemisinin-Piperaquine Mass Drug Administration With or Without Primaquine Dramatically Reduces Malaria in a Highly Endemic Region of Africa.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Comoros; DNA, Protozoan; Dr | 2018 |
G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients.
Topics: Adolescent; Adult; Aged; Antimalarials; Child; Female; Glucosephosphate Dehydrogenase Deficiency; He | 2018 |
Antimalarial activity of primaquine operates via a two-step biochemical relay.
Topics: Aminoquinolines; Antimalarials; Bone Marrow; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System | 2019 |
Primaquine and Chloroquine Fumardiamides as Promising Antiplasmodial Agents.
Topics: Antimalarials; Chloroquine; Erythrocytes; HEK293 Cells; Humans; Malaria, Falciparum; Molecular Struc | 2019 |
Single low-dose primaquine to reduce malaria transmission.
Topics: Antimalarials; Female; Humans; Malaria, Falciparum; Male; Primaquine | 2014 |
Transient lesion in the splenium of the corpus callosum in acute uncomplicated falciparum malaria.
Topics: Acute Disease; Adult; Antimalarials; Artemisinins; Chloroquine; Corpus Callosum; Drug Therapy, Combi | 2014 |
The prevalence of glucose-6-phosphate dehydrogenase deficiency in Gambian school children.
Topics: Adolescent; Alleles; Antimalarials; Child; Child, Preschool; Enzyme-Linked Immunosorbent Assay; Fema | 2014 |
Imported malaria is stable from Africa but declining from Asia.
Topics: Adolescent; Adult; Africa; Aged; Antimalarials; Asia; Atovaquone; Chemoprevention; Child; Child, Pre | 2014 |
Quality of antimalarial drugs and antibiotics in Papua New Guinea: a survey of the health facility supply chain.
Topics: Amodiaquine; Amoxicillin; Antimalarials; Artemether; Artemisinins; Biosimilar Pharmaceuticals; Chlor | 2014 |
Low-dose primaquine for falciparum malaria.
Topics: Antimalarials; Female; Humans; Malaria, Falciparum; Male; Primaquine | 2014 |
Low-dose primaquine for falciparum malaria.
Topics: Antimalarials; Female; Humans; Malaria, Falciparum; Male; Primaquine | 2014 |
Glucose-6-phosphate dehydrogenase deficiency A- variant in febrile patients in Haiti.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Anemia, Hemolytic; Antimalarials; Child; Child, | 2014 |
Amphiphilic dendritic derivatives as nanocarriers for the targeted delivery of antimalarial drugs.
Topics: Animals; Antimalarials; Cell Death; Chloroquine; Dendrimers; Drug Carriers; Drug Delivery Systems; E | 2014 |
Imported malaria in a non-endemic area: the experience of the university of Campinas hospital in the Brazilian Southeast.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anemia; Antimalarials; Artemether; Artemisini | 2014 |
Low-dose primaquine for falciparum malaria.
Topics: Antimalarials; Female; Humans; Malaria, Falciparum; Male; Primaquine | 2014 |
Targeting Plasmodium falciparum transmission with primaquine: same efficacy, improved safety with a lower dose?
Topics: Antimalarials; Dose-Response Relationship, Drug; Drug Resistance; Humans; Malaria, Falciparum; Plasm | 2014 |
Ethics, economics, and the use of primaquine to reduce falciparum malaria transmission in asymptomatic populations.
Topics: Antimalarials; Drug Therapy; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Falciparum; | 2014 |
[Epidemiological characteristics of malaria in the village of Corail, Grand'Anse, Haiti].
Topics: Adolescent; Adult; Aged; Antimalarials; Asymptomatic Diseases; Child; Child, Preschool; Chloroquine; | 2014 |
Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemether, Lumefantrine Drug Combination | 2015 |
Primaquine dosing errors: the human cost of a pharmaceutical anachronism.
Topics: Adult; Antimalarials; Chemoprevention; Cohort Studies; Dosage Forms; Female; Humans; Israel; Malaria | 2015 |
An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa.
Topics: Africa South of the Sahara; Antimalarials; Drug Interactions; Glucosephosphate Dehydrogenase Deficie | 2015 |
Immunoliposome-mediated drug delivery to Plasmodium-infected and non-infected red blood cells as a dual therapeutic/prophylactic antimalarial strategy.
Topics: Animals; Antibodies; Antigens, Protozoan; Antimalarials; Carrier Proteins; Chloroquine; Drug Deliver | 2015 |
Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India.
Topics: Adolescent; Adult; Aged; Antimalarials; Chloroquine; Coinfection; Drug Therapy, Combination; Female; | 2015 |
UK malaria treatment guidelines 2016.
Topics: Adult; Antimalarials; Artemisinins; Artesunate; Breast Feeding; Child; Child, Preschool; Female; Hum | 2016 |
Primaquine to stop transmission of falciparum malaria.
Topics: Antimalarials; Drug Therapy, Combination; Humans; Malaria, Falciparum; Plasmodium falciparum; Primaq | 2016 |
Validation of G6PD Point-of-Care Tests among Healthy Volunteers in Yangon, Myanmar.
Topics: Adult; Antimalarials; Equipment Design; Female; Fluorescence; Glucosephosphate Dehydrogenase; Glucos | 2016 |
Primaquine plus artemisinin combination therapy for reduction of malaria transmission: promise and risk.
Topics: Adult; Antimalarials; Artemisinins; Child; Disease Transmission, Infectious; Drug Therapy, Combinati | 2016 |
[Malaria in the Comoros Archipelago in 2015: status after 15 years of fight].
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Comoros; Female; Humans; In | 2016 |
Persistence of Plasmodium falciparum parasitemia after artemisinin combination therapy: evidence from a randomized trial in Uganda.
Topics: Antimalarials; Artemisinins; Child; Child, Preschool; DNA, Protozoan; Drug Resistance; Drug Therapy, | 2016 |
Sustained efficacy of artesunate-sulfadoxine-pyrimethamine against Plasmodium falciparum in Yemen and a renewed call for an adjunct single dose primaquine to clear gametocytes.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinatio | 2016 |
PFMDR1 POLYMORPHISMS INFLUENCE ON IN VITRO SENSITIVITY OF THAI PLASMODIUM FALCIPARUM ISOLATES TO PRIMAQUINE, SITAMAQUINE AND TAFENOQUINE.
Topics: Aminoquinolines; Antimalarials; Humans; Malaria, Falciparum; Multidrug Resistance-Associated Protein | 2016 |
Development of a pharmacovigilance safety monitoring tool for the rollout of single low-dose primaquine and artemether-lumefantrine to treat Plasmodium falciparum infections in Swaziland: a pilot study.
Topics: Adolescent; Adult; Aged; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Chi | 2016 |
A humanized mouse model for sequestration of Plasmodium falciparum sexual stages and in vivo evaluation of gametocytidal drugs.
Topics: Animals; Antimalarials; Bone Marrow; Disease Models, Animal; Erythrocytes; Humans; Injections, Intra | 2016 |
An optimised age-based dosing regimen for single low-dose primaquine for blocking malaria transmission in Cambodia.
Topics: Adolescent; Adult; Age Factors; Antimalarials; Cambodia; Disease Transmission, Infectious; Drug Ther | 2016 |
Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations.
Topics: Animals; Antimalarials; Asian People; Endemic Diseases; Humans; Malaria, Falciparum; Models, Biologi | 2009 |
Clinical and laboratory features of human Plasmodium knowlesi infection.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Blood Chemical Analysis; Chloroquine; Female; Hemog | 2009 |
Flow cytometry for the evaluation of anti-plasmodial activity of drugs on Plasmodium falciparum gametocytes.
Topics: Anti-Infective Agents; Antimalarials; Artemisinins; Chloroquine; Drug Evaluation, Preclinical; Flow | 2010 |
Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine.
Topics: Administration, Oral; Adolescent; Adult; Anti-Infective Agents; Antimalarials; Artemisinins; Cambodi | 2010 |
Symmetrical peripheral gangrene in childhood falciparum malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Child; Female; Gangrene; Humans; Malaria, Falciparum; Meflo | 2010 |
Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2010 |
Primaquine administration after falciparum malaria treatment in malaria hypoendemic areas with high incidence of falciparum and vivax mixed infection: pros and cons.
Topics: Antimalarials; Cost-Benefit Analysis; Endemic Diseases; Humans; Incidence; Malaria, Falciparum; Mala | 2010 |
Appropriate time for primaquine treatment to reduce Plasmodium falciparum transmission in hypoendemic areas.
Topics: Antimalarials; Artemisinins; Humans; Lactones; Malaria, Falciparum; Plasmodium falciparum; Primaquin | 2010 |
Dynamics of Plasmodium falciparum parasitemia regarding combined treatment regimens for acute uncomplicated malaria, Antioquia, Colombia.
Topics: Administration, Oral; Animals; Antimalarials; Artemisinins; Artesunate; Clinical Protocols; Colombia | 2010 |
Plasmodium knowlesi malaria in children.
Topics: Adolescent; Age Factors; Anemia; Antimalarials; Child; Child, Preschool; Chloroquine; Female; Humans | 2011 |
The potential contribution of mass treatment to the control of Plasmodium falciparum malaria.
Topics: Antimalarials; Humans; Insecticide-Treated Bednets; Malaria, Falciparum; Primaquine | 2011 |
Efficacy of chloroquine plus primaquine treatment and pfcrt mutation in uncomplicated falciparum malaria patients in Rangamati, Bangladesh.
Topics: Administration, Oral; Adolescent; Adult; Antimalarials; Bangladesh; Child; Child, Preschool; Chloroq | 2011 |
Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America.
Topics: Antimalarials; Chloroquine; Drug Resistance; Honduras; Humans; Malaria, Falciparum; Malaria, Vivax; | 2011 |
Tolerability and safety of primaquine in Papua New Guinean children 1 to 10 years of age.
Topics: Aging; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Cohort Studies | 2012 |
Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance.
Topics: Antimalarials; Artemisinins; Cambodia; Drug Resistance; Humans; Malaria, Falciparum; Models, Theoret | 2012 |
New treatment policy of malaria as a part of malaria control program in Indonesia.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Disease Eradication; Drug Resistance; Drug Ther | 2012 |
Focused Screening and Treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant P. falciparum, Pailin, Cambodia.
Topics: Artemisinins; Atovaquone; Base Sequence; Cambodia; Carrier State; Cross-Sectional Studies; Demograph | 2012 |
Primaquine to prevent transmission of falciparum malaria.
Topics: Antimalarials; Artemisinins; Drug Resistance; Drug Therapy, Combination; Hemolysis; Humans; Malaria, | 2013 |
Control of malaria: a successful experience from Viet Nam.
Topics: Antimalarials; Bedding and Linens; Child; Child, Preschool; Communicable Disease Control; Female; He | 2002 |
Prevalence of malaria in Aligarh.
Topics: Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Humans; India; | 2002 |
The clinical and epidemiological features of childhood malaria in a moderately endemic area of Sri Lanka.
Topics: Administration, Oral; Antimalarials; Arthralgia; Case-Control Studies; Child; Child Welfare; Child, | 2002 |
The chemotherapy of rodent malaria. LXI. Drug combinations to impede the selection of drug resistance, part 4: the potential role of 8-aminoquinolines.
Topics: Aminoquinolines; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Drug | 2003 |
The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 strain).
Topics: Antimalarials; Humans; Malaria; Malaria, Falciparum; Panama; Primaquine | 1955 |
The treatment of Plasmodium falciparum infection with chloroquine, with a note on infectivity to mosquitoes of primaquine- and pyrimethamine-treated cases.
Topics: Animals; Antimalarials; Chloroquine; Culicidae; Humans; Malaria, Falciparum; Plasmodium falciparum; | 1956 |
Two worlds of malaria.
Topics: Animals; Antimalarials; Child; Chloroquine; Drug Resistance; Endemic Diseases; Humans; Life Cycle St | 2003 |
Primaquine for prevention of malaria in travelers.
Topics: Adult; Animals; Antimalarials; Chemoprevention; Clinical Trials as Topic; Drug Tolerance; Humans; Ma | 2003 |
Declining mefloquine sensitivity of Plasmodium falciparum along the Thai-Myanmar border.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Resistance; Humans; Malari | 2004 |
Diagnostic and prognostic utility of an inexpensive rapid on site malaria diagnostic test (ParaHIT f) among ethnic tribal population in areas of high, low and no transmission in central India.
Topics: Adult; Antimalarials; Child; Chloroquine; Ethnicity; Female; Humans; India; Infant; Malaria, Falcipa | 2005 |
A 57-year-old man with a 6-day headache and fatigue.
Topics: Antimalarials; Decision Making; Diagnosis, Differential; Fatigue; Headache; Humans; Malaria, Falcipa | 2005 |
Chloroquine and primaquine: combining old drugs as a new weapon against falciparum malaria?
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Therapy, Combination; Humans; Malaria, Fa | 2006 |
The use of primaquine in malaria infected patients with red cell glucose-6-phosphate dehydrogenase (G6PD) deficiency in Myanmar.
Topics: Developing Countries; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythrocytes; | 1994 |
Effectiveness of doxycycline combined with primaquine for malaria prophylaxis.
Topics: Australia; Doxycycline; Drug Evaluation; Drug Therapy, Combination; Humans; Malaria, Falciparum; Mal | 1995 |
Halofantrine in acute malaria.
Topics: Acute Disease; Antimalarials; Drug Resistance, Multiple; Humans; Malaria, Falciparum; Malaria, Vivax | 1994 |
Malaria in Kansas, 1988-1993.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Drug Resistance; Female; Humans; Kansas; Malaria; | 1994 |
Mefloquine level monitoring in patients with multidrug resistant Plasmodium falciparum on the Thai Myanmar border.
Topics: Administration, Oral; Adolescent; Adult; Antimalarials; Cambodia; Chromatography, High Pressure Liqu | 1993 |
[Recurrence problems with preventive primaquine treatment in patients with malaria].
Topics: Adult; Drug Resistance, Microbial; Gastrointestinal Diseases; Humans; Malaria, Falciparum; Malaria, | 1993 |
Interactions among primaquine, malaria infection and other antimalarials in Thai subjects.
Topics: Acute Disease; Administration, Oral; Adult; Drug Interactions; Humans; Malaria, Falciparum; Male; Me | 1993 |
A standard regimen for treatment of plasmodium vivax malaria.
Topics: Antimalarials; Humans; Infant; Malaria, Cerebral; Malaria, Falciparum; Malaria, Vivax; Primaquine; Q | 1996 |
[Will a gametocytocide combined with an antimalarial schizonticide soon be necessary in areas of drug resistance?].
Topics: Animals; Antimalarials; Chloroquine; Drug Combinations; Drug Resistance; Gametogenesis; Humans; Mala | 1997 |
Early diagnosis and treatment of malaria in a refugee population in Sri Lanka.
Topics: Adult; Antimalarials; Blood; Child; Chloroquine; Cost-Benefit Analysis; Developing Countries; Health | 1997 |
[Effect of primaquine on the elimination of sexual forms of Plasmodium falciparum in vivo].
Topics: Animals; Antimalarials; Drug Administration Schedule; Humans; Malaria, Falciparum; Parasitemia; Plas | 1994 |
Primaquine prophylaxis against malaria.
Topics: Antimalarials; Female; Glucosephosphate Dehydrogenase Deficiency; Humans; Malaria, Falciparum; Malar | 1999 |
Cardiopulmonary bypass on a patient with malaria.
Topics: Aged; Antimalarials; Cardiopulmonary Bypass; Female; Heart Diseases; Humans; Malaria, Falciparum; Po | 1999 |
[Prevention of malaria].
Topics: Anti-Bacterial Agents; Antimalarials; Chloroquine; Doxycycline; Female; Humans; Malaria; Malaria, Fa | 1999 |
Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro.
Topics: Amsacrine; Animals; Antimalarials; Chloroquine; Drug Resistance, Multiple; Enzyme Inhibitors; Etopos | 2000 |
Epidemiologic tools for malaria surveillance in an urban setting of low endemicity along the Colombian Pacific coast.
Topics: Animals; Antimalarials; Blood; Blotting, Southern; Chloroquine; Colombia; Cross-Sectional Studies; D | 2000 |
A survey of primaquine prescribing habits in the city of Mumbai.
Topics: Developing Countries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Utilizati | 2000 |
Malaria in Yuanyang, Yunnan, People's Republic of China--new control strategy (1992 -1996).
Topics: Animals; Antimalarials; China; Chloroquine; Communicable Disease Control; Culicidae; DDT; Humans; In | 2000 |
[Does the brief treatment with antimalarials favorably influence drug resistance and recurrences?].
Topics: Animals; Antimalarials; Chloroquine; Drug Resistance; Humans; Malaria; Malaria, Falciparum; Malaria, | 2001 |
Asexual erythrocytic forms of Plasmodium falciparum in asymptomatic American and Korean soldiers serving in Vietnam.
Topics: Animals; Antimalarials; Australia; Chloroquine; Erythrocytes; Humans; Korea; Malaria, Falciparum; Mi | 1967 |
Plasma quinine levels in patients with falciparum malaria when given alone or in combination with tetracycline with or without primaquine.
Topics: Adolescent; Adult; Aged; Animals; Drug Resistance; Drug Therapy, Combination; Humans; Malaria, Falci | 1991 |